Take a look at our latest discoveries here

The Institute is a powerhouse of scientific excellence and innovation. We publish in top level journals including: New England Journal of Medicine, Nature, Nature Biotechnology, Nature Medicine, Cell, J. Exp. Med., The Lancet, The Lancet Infectious Disease and specialty journals including J. Hepatol., Hepatology, Gut, Gastroenterology

HIGHLIGHTS

A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery Crouchet, E., et al. (2021)

A human liver cell atlas reveals heterogeneity and epithelial progenitors
Aizarani, N., et al. (2019)

Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape Colpitts, C.C.,  et al. (2018)

miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis Van Renne N.,  et al. (2018)

Curing chronic hepatitis C-the arc of a medical triumph
Chung, R.T., and Baumert, T.F. (2014)

HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response Hamdane, N., et al. (2019)

A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor
Eller, C., et al. (2020)

Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma Juhling, F., et al. (2021)

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy Lupberger, J. et al. (2011)

RACK1 controls IRES-mediated translation of viruses
Majzoub, K., et al. (2014)

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody Mailly, L., et al. (2015)

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition Nakagawa, S., et al. (2016)

HIGHLIGHTS

The Institute is a powerhouse of scientific excellence and innovation. We publish in top level journals including:
New England Journal of Medicine, Nature, Nature Biotechnology, Nature Medicine, Cell, J. Exp. Med., The Lancet, The Lancet Infectious Disease and specialty journals including J. Hepatol., Hepatology, Gut, Gastroenterology

Aizarani, N., et al. (2019).  “A human liver cell atlas reveals heterogeneity and epithelial progenitors.”
Nature 572(7768), 199-204. doi: 10.1038/s41586-019-1373-2. (IF=42.78)

Chung, R.T., and Baumert, T.F. (2014). “Curing chronic hepatitis C–the arc of a medical triumph.”
N Engl J Med 370(17), 1576-1578. doi: 10.1056/NEJMp1400986. (IF=74.69)

Colpitts, C.C.,  et al. (2018). “Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.”
Gut 67(4), 736-745. doi: 10.1136/gutjnl-2016-312577. (IF=19.82)

Eller, C., et al. (2020). “A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor.”
Nat Commun 11(1), 2707. doi: 10.1038/s41467-020-16517-w. (IF=12.12)

Hamdane, N., et al. (2019). “HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.”
Gastroenterology 156(8), 2313-2329 e2317. doi: 10.1053/j.gastro.2019.02.038.  (IF=20.84)

Juhling, F., et al. (2021). “Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.”
Gut 70(1), 157-169. doi: 10.1136/gutjnl-2019-318918. (IF=19.82)

Lupberger, J. et al. (2011). “EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.”
Nat Med 17(5), 589-595. doi: 10.1038/nm.2341. (IF=36.13)

Mailly, L., et al. (2015). “Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.”
Nat Biotechnol 33(5), 549-554. doi: 10.1038/nbt.3179. (IF=36.55)

Majzoub, K., et al. (2014). “RACK1 controls IRES-mediated translation of viruses.”
Cell 159(5), 1086-1095. doi: 10.1016/j.cell.2014.10.041. (IF=38.63)

Nakagawa, S., et al. (2016). “Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.”
Cancer Cell 30(6), 879-890. doi: 10.1016/j.ccell.2016.11.004. (IF=26.60)

PUBLICATION RECORD

Jühling F, Hamdane N, Crouchet E, Li S, El Saghire H, Mukherji A, Fujiwara N, Oudot MA, Thumann C, Saviano A, Roca Suarez AA, Goto K, Masia R, Sojoodi M, Arora G, Aikata H, Ono A, Tabrizian P, Schwartz M, Polyak SJ, Davidson I, Schmidl C, Bock C, Schuster C, Chayama K, Pessaux P, Tanabe KK, Hoshida Y, Zeisel MB, Duong FH, Fuchs BC, Baumert TF. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut. 2020 Mar 26;gutjnl-2019-318918. doi: 10.1136/gutjnl-2019-318918. Online ahead of print. PMID: 32217639. (IF=19.82)

Olbrich A, Wardemann H, Böhm S, Rother K, Colpitts CC, Wrensch F, Baumert TF, Berg T, Benckert J. Erratum to: Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C. J Infect Dis. 2020 Jun 11;221(12):2084. doi: 10.1093/infdis/jiaa052. PMID: 32061172. (IF=5.02)

Eller C, Heydmann L, Colpitts CC, El Saghire H, Piccioni F, Jühling F, Majzoub K, Pons C, Bach C, Lucifora J, Lupberger J, Nassal M, Cowley GS, Fujiwara N, Hsieh SY, Hoshida Y, Felli E, Pessaux P, Sureau C, Schuster C, Root DE, Verrier ER, Baumert TF. A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor.  Nat Commun. 2020 Jun 1;11(1):2707. doi: 10.1038/s41467-020-16517-w. PMID: 32483149. (IF=12.12)

Rybicka M, Woziwodzka A, Sznarkowska A, Romanowski T, Stalke P, Dręczewski M, Verrier ER, Baumert TF, Bielawski KP. Genetic variation in IL-10 influences the progression of hepatitis B infection. Int J Infect Dis. 2020 Jul;96:260-265. doi: 10.1016/j.ijid.2020.04.079. PMID: 32387446. (IF=3.20)

Tripon S, Mayer P, Svab A, Habersetzer F, Pessaux P, Baumert TF, Enescu I. Intraabdominal urokinase in the treatment of loculated infected ascites in cirrhosis. Clin Res Hepatol Gastroenterol. 2020 Jul 9:S2210-7401(20)30181-9. doi: 10.1016/j.clinre.2020.06.012. PMID: 32654936. (IF=2.72)

Verrier ER, Weiss A, Bach C, Heydmann L, Turon-Lagot V, Kopp A, El Saghire H, Crouchet E, Pessaux P, Garcia T, Pale P, Zeisel MB, Sureau C, Schuster C, Brino L, Baumert TF. Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets. Gut. 2020 Jan;69(1):158-167. doi: 10.1136/gutjnl-2018-317065. PMID: 30833451. (IF=19.82)

Wang YX, Niklasch M, Liu T, Wang Y, Shi B, Yuan W, Baumert TF, Yuan Z, Tong S, Nassal M, Wen YM. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication. J Hepatol. 2020 May;72(5):865-876. doi: 10.1016/j.jhep.2019.12.009. PMID: 31863794. (IF=20.58)

Mayer P, Saviano A, Kassegne L, Baumert TF, Reimund JM, Habersetzer F. Safe administration of corticosteroids in severe ulcerative colitis and active SARS-CoV2 infection. Dig Liver Dis. 2020 Nov;52(11):1257-1258. doi: 10.1016/j.dld.2020.07.022. PMID: 32819861. (IF=3.57)

Aizarani N, Saviano A #, Sagar #,  Mailly LDurand S, Herman J.S., Pessaux P., Baumert T.F.*, Grün D.*A Human Liver Cell Atlas reveals Heterogeneity and Epithelial Progenitors. Nature. 2019 Aug;572(7768):199-204. doi: 10.1038/s41586-019-1373-2. Jul 10. PMID: 31292543. (IF=42.79). *Corresponding authors #co-second authors.

Zhuang X, Magri A, Hill M, Lai AG, Kumar A, Rambhatla SB, Donald CL, Lopez-Clavijo AF, Rudge S, Pinnick K, Chang WH, Wing PAC, Brown R, Qin X, Simmonds P, Baumert TF, Ray D, Loudon A, Balfe P, Wakelam M, Butterworth S, Kohl A, Jopling CL, Zitzmann N, McKeating JA. The circadian clock components BMAL1 and REV-ERBα regulate flavivirus replication. Nat Commun. 2019 Jan 22;10(1):377. doi: 10.1038/s41467-019-08299-7. PubMed PMID: 30670689.

Hamdane N*, Jühling F*, Crouchet E, El Saghire H, Thumann C, Oudot M, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF. HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology. 2019 Jun;156(8):2313-2329.e7. doi: 10.1053/j.gastro.2019.02.038. Epub 2019 Mar 2. PMID: 30836093. (*co-first author). (IF=17.37)

Schwenzer H, Jühling F, Chu A, Pallett LJ, Baumert TF, Maini M, Fassati A. Oxidative stress triggers selective tRNA retrograde transport in human cells during integrated stress response. Cell reports. 2019 Mar 19;26(12):3416-3428.e5. doi: 10.1016/j.celrep.2019.02.07 PMID: 30893612. (IF=8.11)

Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection. Antiviral Res, 2019,162:136-141. doi: 10.1016/j.antiviral.2018.12.018. PMID: 30599173. (IF= 4.1)

Hoogeveen RC, Robidoux MP, Schwarz T, Heydmann L, Cheney JA, Kvistad D, Aneja J, Melgaço JG, Fernandes CA, Chung RT, Boonstra A, Kim AY, Baumert TF, Timm J, Lewis-Ximenez LL, Tonnerre P, Lauer GM. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. Gut. 2019, 68, 893-904,doi:10.1136/gutjnl-2018-316644. PMID: 30580250. (IF= 19.82)

Herzog K*, Bandiera S*, Pernot S, Fauvelle C, Jühling F, Weiss A, Bull A, Durand SC, Chane-Woon-Ming B, Pfeffer S, Mercey M, Lerat H, Meunier J-C, Raffelsberger W, Brino L, Baumert TF, Zeisel MB. Functional microRNA screen uncovers O-linked N-acetylglucosamine transferase as a host factor modulating hepatitis C virus morphogenesis and infectivity. Gut 2020 Feb;69(2):380-392. doi: 10.1136/gutjnl-2018-317423. Epub 2019 May 10. PMID:31076402. (IF=19.82) (*co-first author).

Lupberger J, Croonenborghs T, Roca Suarez AA, Van Renne N, Jühling F, Oudot MA, Virzì A, Bandiera S, Jamey C, Meszaros G, Brumaru D, Mukherji A, Durand SC, Heydmann L, Verrier ER, El Saghire H, Hamdane N, Bartenschlager R, Fereshetian S, Ramberger E, Sinha R, Nabian M, Everaert C, Jovanovic M, Mertins P, Carr SA, Chayama K, Dali-Youcef N, Ricci R, Bardeesy NM, Fujiwara N, Gevaert O, Zeisel MB, Hoshida Y, Pochet N, Baumert TF. Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development. Gastroenterology. 2019, 157:537-551.e9. doi: 10.1053/j.gastro.2019.04.003. PMID: 30978357. (IF= 17.37).

Wrensch F, Ligat G, Heydmann L, Schuster C, Zeisel MB, Pessaux P, Habersetzer F, King BJ, Tarr AW, Ball JK, Winkler M, Pöhlmann S, Keck ZY, Foung SKH, Baumert TF. IFITMs mediate viral evasion in acute and chronic hepatitis C virus infection. Hepatology. 2019 Nov;70(5):1506-1520. doi: 10.1002/hep.30699. Epub 2019 Jun 21. PMID: 31062385. (IF=14.68).

Olbrich A, Wardemann H, Böhm S, Rother K, Colpitts CC, Wrensch F, Baumert TF, Berg T, Benckert J.Repertoire and neutralizing activity of antibodies against E2 peptide in patients with spontaneous resolution of hepatitis C. J Infect Dis. 2019 Aug 30;220(7):1209-1218. doi: 10.1093/infdis/jiz274. PMID: 31165162 (IF=5.02)

Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH. Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. PLoS Pathog. 2019 May 17;15(5):e1007772. doi: 10.1371/journal.ppat.1007772. eCollection 2019 May. PMID: 31100098. (IF=6.22)

Bou About G, Thiebault E, Wattenhofer-Donzé M, Jacobs H, Guimond A, Sorg T, Robinet E, Baumert TF, Monassier L, Herault Y. Ultrasound-Guided Approaches to Improve Orthotopic Mouse Xenograft Models for Hepatocellular Carcinoma. Curr. Protoc Mouse Biol. 2019 Jun;9(2):e62. doi: 10.1002/cpmo.62. Epub 2019 May 30. PMID: 31145554. (IF= 1.83).

Dali-Youcef N, Vix M, Costantino F, El-Saghire H, Lhermitte B, Callari C, D’Agostino J, Perretta S, Paveliu S, Gualtierotti M, Dumeny E, Oudot MA, Jaulin A, Dembélé D, Zeisel MB, Tomasetto C, Baumert TF, Doffoël M. Interleukin-32.Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance. Hepatol Commun. 2019 Jul 19;3(9):1205-1220. doi: 10.1002/hep4.1396. eCollection. 2019 Sep. PMID: 31497742

Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut. 2018 May;67(5):953-962. doi: 10.1136/gutjnl-2016-312270. PubMed PMID:28159835
Van Renne N, Roca Suarez AA, Duong FH, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut, 2018 Epub 2017 Feb 3., 67(5):953-962. (IF=17.02)
Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape. Gut. 2017 Mar 30. pii: gutjnl-2016-312577. doi:10.1136/gutjnl-2016-312577. PMID: 28360099. (IF=17.02)
Ernst FGM, Erber L, Sammler J, Jühling F, Betat H, Mörl M. Cold adaptation of tRNA nucleotidyltransferases: A tradeoff in activity, stability and fidelity. RNA Biol. 2018 Jan 2;15(1):144-155. doi: 10.1080/15476286.2017.1391445. PMID: 29099323. (IF=5.22)
Verrier ER, Yim SA, Heydmann L, El Saghire H, Bach C, Turon-Lagot V, Mailly L, Durand SC, Lucifora J, Durantel D, Pessaux P, Manel N, Hirsch I, Zeisel MB, Pochet N, Schuster C, Baumert TF. Hepatitis B virus evasion from cGAS sensing in human hepatocytes. Hepatology. 2018 Apr 20. doi: 10.1002/hep.30054. PMID: 29679386.(IF=14.08)
Douam F, Fusil F, Enguehard M, Dib L, Nadalin F, Schwaller L, Hrebikova G, Mancip J, Mailly L, Montserret R, Ding Q, Maisse C, Carlot E, Xu K, Verhoeyen E, Baumert TF, Ploss A, Carbone A, Cosset FL, Lavillette D. A protein coevolution method uncovers critical features of the Hepatitis C Virus fusion mechanism. PLoS Pathog. 2018 Mar 5;14(3):e1006908. doi: 10.1371/journal.ppat.1006908. PMID: 29505618. (IF=6.16)
Riva L, Song OR, Prentoe J, Helle F, L’homme L, Gattolliat CH, Vandeputte A, Fénéant L, Belouzard S, Baumert TF, Asselah T, Bukh J, Brodin P, Cocquerel L, Rouillé Y, Dubuisson J. Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry. J Virol. 2018, Apr 27;92(10). pii: e01982-17. doi: 10.1128/JVI.01982-17. PMID: 29491159. (IF=4.37)
Mutz P, Metz P, Lempp FA, Bender S, Qu B, Schöneweis K, Seitz S, Tu T, Restuccia A, Frankish J, Dächert C, Schusser B, Koschny R, Polychronidis G, Schemmer P, Hoffmann K, Baumert TF, Binder M, Urban S, Bartenschlager R. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon. Gastroenterology. 2018 May; 154(6):1791-1804.e22. doi: 10.1053/j.gastro.2018.01.044. PMID: 29410097.(IF=20.77)
Moustafa RI, Haddad JG, Linna L, Hanoulle X, Descamps V, Mesalam AA, Baumert TF, Duverlie G, Meuleman P, Dubuisson J, Lavie M. Functional study of the C-terminal part of hepatitis C virus E1 ectodomain. J Virol. 2018 Aug 1. pii: JVI.00939-18. doi: 10.1128/JVI.00939-18. PMID:30068644. (IF=4.37)
Li S, Ghoshal S, Sojoodi M, Arora G, Masia R, Erstad DJ, Lanuti M, Hoshida Y, Baumert TF, Tanabe KK, Fuchs BC. Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. J Gastrointest Surg. 2018 Oct 26. doi: 10.1007/s11605-018-4004-6. PMID: 30367397. (IF=2.81)
Hoogeveen RC, Robidoux MP, Schwarz T, Heydmann L, Cheney JA, Kvistad D, Aneja J, Melgaço JG, Fernandes CA, Chung RT, Boonstra A, Kim AY, Baumert TF, Timm J, Lewis-Ximenez LL, Tonnerre P, Lauer GM. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. Gut. 2018 Dec 22. pii: gutjnl-2018-316644. doi:10.1136/gutjnl-2018-316644. PMID: 30580250. (IF= 17.02)
Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection. Antiviral Res. 2018 Dec 30;162:136-141. doi: 10.1016/j.antiviral.2018.12.018. PMID: 30599173. (IF= 4.30)
Li C, Wang Y, Liu T, Niklasch M, Qiao K, Durand S, Chen L, Liang M, Baumert TF, Tong S, Nassal M, Wen YM, Wang YX. An E. coli-produced single-chain variable fragment (scFv) targeting hepatitis B virus surface protein potently inhibited virion secretion. Antiviral Res. 2018 Dec 30;162:118-129. doi:10.1016/j.antiviral.2018.12.019. PMID: 30599174. (IF= 4.30)
Coulter ME, Dorobantu CM, Lodewijk GA, Delalande F, Cianferani S, Ganesh VS, Smith RS, Lim ET, Xu CS, Pang S, Wong ET, Lidov HGW, Calicchio ML, Yang E, Gonzalez DM, Schlaeger TM, Mochida GH, Hess H, Lee WA, Lehtinen MK, Kirchhausen T, Haussler D, Jacobs FMJ, Gaudin R, Walsh CA. The ESCRT-III Protein CHMP1A Mediates Secretion of Sonic Hedgehog on a Distinctive Subtype of Extracellular Vesicles. Cell Rep. 2018 Jul 24;24(4):973-986.e8. doi: 10.1016/j.celrep.2018.06.100. PMID: 30044992. (IF= 8.03)
Baze A, Parmentier C, Hendriks DFG, Hurrell T, Heyd B, Bachellier P, Schuster C, Ingelman-Sundberg M, Richert L. Three-Dimensional Spheroid Primary Human Hepatocytes in Monoculture and Coculture with Nonparenchymal Cells. Tissue Eng Part C Methods. 2018 Sep;24(9):534-545. doi: 10.1089/ten.TEC.2018.0134. PMID: 30101670. (IF = 3.50)

Colpitts CC, Tawar RG, Mailly L, Thumann C, Heydmann L, Durand SC, Xiao F, Robinet E, Pessaux P, Zeisel MB, Baumert TF. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape. Gut. 2017 Mar 30. pii: gutjnl-2016-312577. doi: 10.1136/gutjnl-2016-312577.PubMed PMID: 28360099.

Haddad JG, Rouillé Y, Hanoulle X, Descamps V, Hamze M, Dabboussi F, Baumert TF, Duverlie G, Lavie M, Dubuisson J. Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. J Virol. 2017 Mar 29;91(8). pii: e00048-17. doi: 10.1128/JVI.00048-17. Print 2017 Apr 15. PubMed PMID: 28179528; PubMed Central PMCID: PMC5375667.

Haqshenas G, Wu J, Simpson KJ, Daly RJ, Netter HJ, Baumert TF, Doerig C. Signalome-wide assessment of host cell response to hepatitis C virus. Nat Commun.2017 May 8;8:15158. doi: 10.1038/ncomms15158. PubMed PMID: 28480889.

Van Renne N, Roca Suarez AA, Duong FH, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut, 2017 Feb 3. pii: gutjnl-2016-312270. doi: 10.1136/gutjnl-2016-312270.

Farquhar MJ, Humphreys IS, Rudge SA, Wilson GK, Bhattacharya B, Ciaccia M, Hu K, Zhang Q, Mailly L, Reynolds GM, Aschcroft M, Balfe P, Baumert TF, Roessler S, Wakelam MJ, McKeating JA. Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication. J Hepatol, 2017 Jan 23. pii: S0168-8278(17)30013-2. doi: 10.1016/j.jhep.2017.01.009.

Khera T, Todt D, Vercauteren K, McClure CP, Verhoye L, Farhoudi A, Bhuju S, Geffers R, Baumert TF, Steinmann E, Meuleman P, Pietschmann T, Brown RJ. Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. Antiviral Research, 2017, Jan 3. PMID:28062191.

Manzoni G, Marinach C, Topçu S, Briquet S, Grand M, Tolle M, Gransagne M, Lescar J, Andolina C, Franetich JF, Zeisel MB, Huby T, Rubinstein E, Snounou G, Mazier D, Nosten F, Baumert TF, Silvie O. Plasmodium P36 determines host cell receptor usage during sporozoite invasion. eLife. 2017; May 16;6.pii:e25903.doi:10.7554/eLife.25903.

Lucifora J, Salvetti A, Marniquet X, Mailly L, Testoni B, Fusil F, Inchauspé A, Michelet M, Michel ML, Levrero M, Cortez P, Baumert TF, Cosset FL, Challier C,Zoulim F, Durantel D. Detection of the hepatitis B virus (HBV)covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. Antiviral Res. 2017 Jul 11;145:14-19. doi:10.1016/j.antiviral.2017.07.006. PubMed PMID:28709657.

Fauvelle C, Lambotin M, Heydmann L, Prakash E, Bhaskaran S, Vishwaraman M, Baumert TF, Moog C. A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry. Hepatol Int. 2017 Jul 11. doi:10.1007/s12072-017-9809-y. PubMed PMID: 28698985.

Binder H, Hopp L, Schweiger MR, Hoffmann S, Jühling F, Kerick M, Timmermann B, Siebert S, Grimm C, Nersisyan L, Arakelyan A, Herberg M, Buske P, Loeffler-Wirth H, Rosolowski M, Engel C, Przybilla J, Peifer M, Friedrichs N, Moeslein G, Odenthal M, Hussong M, Peters S, Holzapfel S, Nattermann J, Hueneburg R, Schmiegel W, Royer-Pokora B, Aretz S, Kloth M, Kloor M, Buettner R, Galle J, Loeffler M. Genomic and transcriptomic heterogeneity of colorectal tumors arising in Lynch Syndrome. J Pathol. 2017 Jul 20. doi: 10.1002/path.4948. PubMed PMID: 28727142.

Desombere I, Mesalam AA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck ZY, Farhoudi A, Vercauteren K, Weening KE, Baumert TF, Patel AH, Foung SKH, Ball J, Leroux-Roels G, Meuleman P. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. Antiviral Res. 2017 Oct 23. pii: S0166-3542(17)30430-8.doi:10.1016/j.antiviral.2017.10.015. PubMed PMID: 29074219.

Wolski D, Foote PK, Chen DY, Lewis-Ximenez LL, Fauvelle C, Aneja J, Walker A, Tonnerre P, Torres-Cornejo A, Kvistad D, Imam S, Waring MT, Tully DC, Allen TM, Chung RT, Timm J, Haining WN, Kim AY, Baumert TF, Lauer GM. Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8(+) T Cells in Chronic versus Acute Infection. Immunity. 2017 Oct 17;47(4):648-663.e8. doi: 10.1016/j.immuni.2017.09.006. PubMed PMID: 29045899.

Zhang Z, Meszaros G, He WT, Xu Y, de Fatima Magliarelli H, Mailly L, Mihlan M, Liu Y, Puig Gámez M, Goginashvili A, Pasquier A, Bielska O, Neven B, Quartier P, Aebersold R, Baumert TF, Georgel P, Han J, Ricci R. Protein kinase D at the Golgi controls NLRP3 inflammasome activation. J Exp Med. 2017 Sep 4;214(9):2671-2693. doi: 10.1084/jem.20162040. Epub 2017 Jul 17. PubMed PMID: 28716882; PubMed Central PMCID: PMC5584123.

Desombere I, Fafi-Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, Verhoye L, Cole S, McKeating JA, Leroux-Roels G, Baumert TF, Patel AH, Meuleman P. Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. Hepatology, 2016 Apr;63(4):1120-34. doi: 10.1002/hep.28428. Epub 2016 Feb 22.

Verrier ER, Colpitts CC, Bach C, Heydmann L, Weiss A, Renaud M, Durand SC, Habersetzer F, Durantel D, Abou-Jaoudé G, Lopez Ledesma MM, Felmlee DJ, Soumillon M, Croonenborghs T, Pochet N, Nassal M,Schuster C, Brino L, Sureau C, Zeisel MB, Baumert TF. A targeted functional RNAi screen uncovers Glypican 5 as an entry factor for hepatitis B and D viruses. Hepatology, 2016, 63(1):35-48 doi:10.1002/hep.28013. (Epub ahead of print)

Fauvelle C*, Felmlee DJ*, Crouchet E, Lee JY, Heydmann L, Lefèvre M, Magri A, Hiet MS, Fofana I, Habersetzer F, Foung SKH, Milne R, Patel AH, Vercauteren K, Meuleman P, Zeisel MB, Bartenschlager R, Schuster C, Baumert TF *Equal contributors. Apolipoprotein E mediates evasion from hepatitis C virus neutralizing antibodies Gastroenterology, 2016, 150(1):206-217, doi: http://dx.doi.org/10.1053/j.gastro.2015.09.014.

Meredith LW, Hu K, Cheng X, Howard CR, Baumert TF, Balfe P, Van de Graaf KF, Protzer U, McKeating JA. Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors. J. Gen. Virol., 2016Jan;97(1):121-7. doi: 10.1099/jgv.0.000317. Epub 2015 Oct 16.

Bandiera S, Pernot S, El Saghire H, Durand SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, Schuster C, Pessaux P, Heim MH, Baumert TF, Zeisel MB. HCV-induced up-regulation of miR-146a-5p in hepatocytes promotes viral infection and deregulates metabolic pathways associated with liver disease pathogenesis. J Virol. 2016, 90, 6387-400. (Epub ahead of print).

Moenne-Loccoz R, Severac F, Baumert TF, Habersetzer F. Usefulness of corticosteroids as first-line therapy in patients with acute severe autoimmune hepatitis. J. Hepatol., 2016, 65, 444-6.

Raziorrouh B, Sacher K, Tawar RG, Emmerich F, Neumann-Haefelin C, Baumert TF, Thimme R, Boettler T. Virus-Specific CD4+ T Cells Have Functional and Phenotypic Characteristics of Follicular T-Helper Cells in Patients With Acute and Chronic HCV Infections. Gastroenterology, 2016, 150, 696-706. Nov 14. pii: S0016-5085(15)01622-4. doi: 10.1053/j.gastro.2015.11.005. (Epub ahead of print).

Piardi T, Méméo R, Renard Y, Amendola M, Bruno O, Habersetzer F, Baumert T, Pessaux P, Sommacale D. Management of large hepatocellular carcinoma by sequential transarterial chemoembolization and portal vein embolization. Minerva Chir., 2016, 71, 192-200.

Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, Baumert TF. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev. Vaccines. 2016, Jun 13:1-10 (epub ahead of print).

Colpitts CC, El-Saghire H, Pochet N, Schuster C, Baumert TF. High-throughput approaches to unravel hepatitis C virus-host interactions. Virus Res. 2016, 218, 18-24. (IF=2.52)Keck ZY, Wang Y, Lau P, Lund G, Rangarajan S,

Fauvelle C, Liao GC, Holtsberg FW, Warfield KL, Aman MJ, Pierce BG, Fuerst TR, Bailey JR, Baumert TF, Mariuzza RA, Kneteman NM, Foung SK. Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute HCV infection. Hepatology. 2016 Sep 19. doi: 10.1002/hep.28850. (Epub ahead of print)

Crouchet E, Lefèvre M, Verrier ER, Oudot MA, Baumert TF, Schuster C. Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux. Gut. 2016 Sep 8. pii: gutjnl-2015-311289. doi: 10.1136/gutjnl-2015-311289. (Epub ahead of print)

Tawar RG, Heydmann L, Bach C, Schüttrumpf J, Chavan S, King BJ, McClure CP, Ball JK, Pessaux P, Habersetzer F, Bartenschlager R, Zeisel MB, Baumert TF. Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin. Hepatology. 2016 Aug 17. doi: 10.1002/hep.28767. (IF=11.71)Verrier ER, Colpitts CC, Bach C, Heydmann L, Zona L, Xiao F, Thumann C, Crouchet E, Gaudin R, Sureau C, Cosset FL, McKeating JA, Pessaux P, Hoshida Y, Schuster C, Zeisel MB, Baumert TF. Solute carrier NTCP regulates innate antiviral immune responses targeting hepatitis C virus infection of hepatocytes. Cell Rep., 2016, 17:1357-1368. Doi:10.1016/j.celrep.2016.09.084.

Van Renne N, Roca Suarez AA, Duong FH, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF, Lupberger J. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut, 2017 Feb 3. pii: gutjnl-2016-312270. doi: 10.1136/gutjnl-2016-312270. (Epub ahead of print)

Farquhar MJ, Humphreys IS, Rudge SA, Wilson GK, Bhattacharya B, Ciaccia M, Hu K, Zhang Q, Mailly L, Reynolds GM, Aschcroft M, Balfe P, Baumert TF, Roessler S, Wakelam MJ, McKeating JA. Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication. J Hepatol, 2017 Jan 23. pii: S0168-8278(17)30013-2. doi: 10.1016/j.jhep.2017.01.009. (Epub ahead of print)

Khera T, Todt D, Vercauteren K, McClure CP, Verhoye L, Farhoudi A, Bhuju S, Geffers R, Baumert TF, Steinmann E, Meuleman P, Pietschmann T, Brown RJ. Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. Antiviral Research, 2017, Jan 3. PMID:28062191.

Piardi T, Memeo R, Renard Y, Ammendola M, Bruno O, Habersetzer F, Baumert T, Pessaux P, Sommacale D. Management of large hepatocellular carcinoma by sequential transarterial chemoembolization and portal vein embolization: a systematic review of the literature. Minerva Chir. 2016 Jun;71(3):192-200.Pierce BG, Keck ZY, Lau P, Fauvelle C, Gowthaman R, Baumert TF, Fuerst TR, Mariuzza RA, Foung SK.Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design.Proc Natl Acad Sci U S A. 2016 Oct 26. pii: 201614942. (Epub ahead of print)

Wu T, Heuillard E, Lindner V, Bou About G, Ignat M, Dillenseger JP, Anton N, Dalimier E, Gossé F, Fouré G, Blindauer F, Giraudeau C, El-Saghire H, Bouhadjar M, Calligaro C, Sorg T, Choquet P, Vandamme T, Ferrand C, Marescaux J, Baumert TF, Diana M, Pessaux P, Robinet E.Multimodal imaging of a humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice.Sci Rep. 2016 Oct 14;6:35230. doi: 10.1038/srep35230.

Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu ML, Chuang WL, Dai CY, Kobayashi M, Kumada H, Beppu T, Baba H, Mahajan M, Nair VD, Lanuti M, Villanueva A, Sangiovanni A, Iavarone M, Colombo M, Llovet JM, Subramanian A, Tager AM, Friedman SL, Baumert TF, Schwarz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y. Precision Liver Cancer Prevention Consortium. Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.Cancer Cell. 2016 Dec 12;30(6):879-890. doi: 10.1016/j.ccell.2016.11.004.

Vercauteren K, Brown RJ, Mesalam AA, Doerrbecker J, Bhuju S, Geffers R, Van Den Eede N, McClure CP, Troise F, Verhoye L, Baumert T, Farhoudi A, Cortese R, Ball JK, Leroux-Roels G, Pietschmann T, Nicosia A, Meuleman P.Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.Gut. 2016 Dec;65(12):2029-2034. doi: 10.1136/gutjnl-2014-309045.

Aguet F, Upadhyayula S, Gaudin R, Chou YY, Cocucci E, He K, Chen BC, Mosaliganti K, Pasham M, Skillern W, Legant WR, Liu TL, Findlay G, Marino E, Danuser G, Megason S, Betzig E, Kirchhausen T. Membrane dynamics of dividing cells imaged by lattice light-sheet microscopy.Mol Biol Cell. 2016 Nov 7;27(22):3418-3435.

Jühling F, Kretzmer H, Bernhart SH, Otto C, Stadler PF, Hoffmann S.metilene: fast and sensitive calling of differentially methylated regions from bisulfite sequencing data.Genome Res. 2016 Feb;26(2):256-62. doi: 10.1101/gr.196394.115.

Bernhart SH, Kretzmer H, Holdt LM, Jühling F, Ammerpohl O, Bergmann AK, Northoff BH, Doose G, Siebert R, Stadler PF, Hoffmann S.Changes of bivalent chromatin coincide with increased expression of developmental genes in cancer.Sci Rep. 2016 Nov 23;6:37393. doi: 10.1038/srep37393.

Chou YY, Krupp A, Kaynor C, Gaudin R, Ma M, Cahir-McFarland E, Kirchhausen T.Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9.Sci Rep. 2016 Nov 14;6:36921. doi: 10.1038/srep36921.

Chou YY, Cuevas C, Carocci M, Stubbs SH, Ma M, Cureton DK, Chao L, Evesson F, He K, Yang PL, Whelan SP, Ross SR, Kirchhausen T, Gaudin R.Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor.J Virol. 2016 Apr 14;90(9):4494-510. doi: 10.1128/JVI.00103-16.

Mailly L, Xiao F*, Lupberger J*, Wilson GK, Leboeuf C, Aubert P, Duong FHT, Fofana I, Thumann C, Bandiera S, Lutgehetmann M, Volz T, Davis C, Harris HJ, Girardi E, Chane-Woon-Ming B, Fletcher N, Bartenschlager R, Pessaux P, Meuleman P, Villa P, Pfeffer S, Heim MH, Zeisel MB, Neunlist M, Dandri M, McKeating JA, Robinet E#, Baumert TF#. Clearance of persistent hepatitis C virus infection using a monoclonal antibody specific for tight junction protein claudin-1. Nat. Biotechnol., 2015, 33(5), 549-54.*Authors contributed equally, #Authors contributed equally.

Xiao F*, Fofana I*, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoël M, Leyssen P, Neyts J, Zeisel MB, Baumert TF. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut, 2015, 64(3), 483-94. *Authors contributed equally.

Tawar RG, Colpitts CC, Timm J, Fehm T, Roggendorf M, Meisel H, Meyer N, Habersetzer F, Cosset FL, Berg T, Zeisel MB, Baumert TF. Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties. Hepatology, 2015, 62(3), 726-36.

Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, Brand-Sarif T, Chang P, Kivett V, Castells L, Prieto M, Fontana RJ, Baumert TF, Coilly A, Londono MC, Habersetzer F. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. Hepatology, 2015, 61, 1485-94.

Lupberger J, Casanova C, Fischer B, Weiss A, Fofana I, Fontaine N, Fujiwara T, Renaud M, Kopp A, Schuster C, Brino L, Baumert TF, Thoma C. PI4K-beta and MKNK1 are regulators of hepatitis C virus IRES-dependent translation. Sci. Rep., 2015, 5, 13344.

Gerold G, Meissner F, Bruening J, Welsch K, Perin PM, Baumert TF, Vondran FW, Kaderali L, Marcotrigiano J, Khan AG, Mann M, Rice CM, Pietschmann T. Quantitative Proteomics Identifies Serum Response Factor Binding Protein 1 as a Host Factor for Hepatitis C Virus Entry. Cell Rep., 2015, 12(5), 864-78.

Leboeuf C, Roser-Schilder J, Lambotin M, Durand S, Wu T, Fauvelle C, Su B, Bôle-Richard E, Deschamps M, Ferrand C., Tiberghien P, Pessaux P, Baumert TF, Robinet E. Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes : an in vitro proof-of-concept. Gene Ther., 2015, 22(2), 172-180.

Wu T, Bour G, Durand S, Lindner V, Gosse F, Zona L, Certoux JM, Diana M, Baumert TF, Marescaux J, Mutter D, Pessaux P, Robinet E. Use of a Closed Culture System to Improve the Safety of Lentiviral Vector Production. Hum. Gene Ther. Methods, 2015, 26, 197-210.

Wu T, Leboeuf C, Durand S, Su B, Deschamps M, Zhang X, Ferrand C, Pessaux P, Robinet E. Suicide gene-modified killer cells as an allogeneic alternative to autologous cytokine-induced killer cell immunotherapy of hepatocellular carcinoma. Mol. Med. Reports, 2016, 13, 2645-2654.

Hallet J, Soler L, Diana M, Mutter D, Baumert TF, Habersetzer F, Marescaux J, Pessaux P. Trans-thoracic minimally invasive liver resection guided by augmented reality. J. Am. Coll. Surg., 2015, 220(5), e55-60.

Fletcher NF, Humphreys E, Jennings E, Osburn W, Lissauer S, Wilson GK, Van, ISC, Baumert TF, Balfe P, Afford S, McKeating JA. Hepatitis C virus infection of cholangiocarcinoma cell lines. J. Gen. Virol., 2015, 96(Pt 6), 1380-8.

Calattini S, Fusil F, Mancip J, Dao Thi VL, Granier C, Gadot N, Scoazec JY, Zeisel M, Baumert TF, Lavillette D, Dreux M, Cosset FL. Functional and Biochemical Characterization of HCV Particles Produced in a Humanized Liver Mouse Model. J. Biol. Chem., 2015, 290(38), 23173-87.

Fénéant L, Potel J, François C, Sané F, Douam F, Belouzard S, Calland N, Vausselin T, Rouillé Y, Descamps V, Baumert TF, Duverlie G, Lavillette D, Hober D, Dubuisson J, Wychowski C, Cocquerel L. New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A. J. Virol.; 2015, 89(16), 8346-64.

Diana M, Halvax P, Mertz D, Legner A, Brulé JM, Robinet E, Mutter D, Pessaux P, Marescaux J. Improving Echo-Guided Procedures Using an Ultrasound-CT Image Fusion System. Surg. Innov., 2015, 22, 217-22.

Bonetta AC, Mailly L, Robinet E, Travé G, Masson M, Deryckere F. Artificial microRNAs against the viral E6 protein provoke apoptosis in HPV positive cancer cells. Biochem. Biophys. Res. Commun., 2015, 465(4), 658-64.

Zeisel MB*, Lucifora J*, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F. Towards an HBV cure: state-of-the-art and unresolved questions – report of the ANRS workshop on HBV cure. Gut, 2015, 64(8), 1314-26. *the authors contributed equally.

Colpitts CC, Baumert TF. Viral hepatitis: A new HCV cell culture model for the next clinical challenges. Nat. Rev. Gastroenterol. Hepatol., 2015, 12(11), 611-3.

Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122 – a key factor and therapeutic target in liver disease. J. Hepatol., 2015, 62(2), 448-457.

Colpitts CC, Zeisel MB, Baumert TF. When one receptor closes, another opens: Claudins and the hepatitis C virus E1 glycoprotein. Hepatology, 2015, 62(4), 991-3.

Verrier ER, Wieland S, Baumert TF. Retinoic acid-inducible gene 1 and sensing of hepatitis B virus revisited. Hepatology, 2015, 62(3), 970-2.

Tawar RG, Colpitts CC, Lupberger J, El-Saghire H, Zeisel MB, Baumert TF. Claudins and pathogenesis of viral infection. Semin. Cell Dev. Biol., 2015, 42, 39-46.

Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB. Host-targeting agents for treatment of hepatitis B virus infection. Curr. Opin. Virol., 2015, 14, 41-6.

Zeisel MB, Crouchet E, Baumert TF, Schuster C. Host-targeting agents to prevent and cure hepatitis C virus infection. Viruses, 2015, 7(11), 5659-85.

Colpitts CC, Lupberger J, Doerig C, Baumert TF. Host cell kinases and the hepatitis C virus life cycle. Biochim. Biophys. Acta, 2015, 1854(10PtB), 1657-62.

Hafirassou ML, Meignin C, Baumert T, Schuster C. From fly to man: RACK1, an essential actor of the dependent viral translation of IRES. Med. Sci., 2015, 31(5), 469-72.

Bôle-Richard E, Deschamps M, Ferrand C, Robinet E. Editorial: improving the safety of cell therapy products by suicide gene transfer. Front. Pharmacol., 2015, 6, 174.

Mailly L, Zeisel MB, Baumert TF. Locked outside: cure of chronic hepatitis C using an entry inhibitor. Med. Sci. (Paris), 2015, 31(12), 1075-7.

Colpitts CC, Verrier ER, Baumert TF. Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections. ACS Infect Dis. 2015, 1(9), 420-7.

Majzoub K, Hafirassou ML, Meignin C, Goto A., Marzi S., Fedorova A., Verdier Y, Vinh J., Hoffmann JA, Martin F., Baumert TF#, Schuster C*#, Imler JL*#. The ribosomal protein RACK1 is a specific host factor required for IRES-mediated translation of fly and human viruses. Cell, 2014, 159(5), 1086-95. *Corresponding authors, #co-senior authors.

Xiao F*, Fofana I*, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoël M, Leyssen P, Neyts J, Zeisel MB, Baumert TF. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut, 2014, 64, 483-94.*Authors contributed equally.

Duong FHT*, Trincucci G*, Boldanova T, Calabrese D, Campana B, Krol I, Durand SC, Heydmann L, Zeisel MB, Baumert TF, Heim MH. Hepatic IFN-l receptor 1 expression is induced in chronic hepatitis C and correlates with IFN-l3 minor alleles and with non-response to IFN-α therapies. J. Exp. Med., 2014, 211, 857-68. *Authors contributed equally.

Douam F, Thi VL, Maurin G, Fresquet J, Mompelat D, Zeisel MB, Baumert TF, Cosset FL, Lavillette D. Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry. Hepatology, 2014, 59, 776-88.

Leboeuf C*, Mailly L*, Wu T*, Bour G, Durand S, Brignon N, Ferrand C, Borg C, Tiberghien P, Thimme R, Pessaux P, Marescaux J, Baumert TF, Robinet E. In vivo proof-of-concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells. Mol. Ther., 2014, 22, 634-44. *Authors contributed equally.

Xiao F*, Fofana I*, Heydmann L, Barth H, Soulier E, Habersetzer F, Doffoël M, Bukh J, Patel AH, Zeisel MB, Baumert TF. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PloS Pathogens, 2014, 10, e1004128. *Authors contributed equally.

Mertz D, Affolter-Zbaraszczuk C, Barthès J, Cui J, Caruso F, Baumert TF, Voegel JC, Ogier J, Meyer F. Templated assembly of albumin-based nanoparticles for simultaneous gene silencing and magnetic resonance imaging. Nanoscale, 2014, 6, 11676-80.

Leboeuf C, Roser-Schilder J, Lambotin M, Durand S, Wu T, Fauvelle C, Su B, Bole-Richard E, Deschamps M, Ferrand C., Tiberghien P, Pessaux P, Baumert TF, Robinet E. Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes : an in vitro proof-of-concept. Gene Ther., 2014, 22, 172-80.

Habersetzer F, Moenne-Loccoz R, Meyer N, Schvoerer E, Simo-Noumbissie P, Dritsas S, Baumert TF, Doffoël M. Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection. Liver Int., 2014, 35, 130-9.

Lefèvre M, Felmlee DJ, Parnot M, Baumert TF, Schuster C. Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E. PLoS One, 2014, 9, e95550.

Lavie M, Sarrazin S, Montserret R, Descamps V, Baumert T, Duverlie G, Séron K, Penin F, Dubuisson J. Identification of conserved residues in HCV envelope glycoprotein E2 modulating virus dependence on CD81 and SRB1 entry factors. J. Virol., 2014, 88, 10584-97.

Bankwitz D, Vieyres G, Hueging K, Bitzegeio J, Doepke M, Chhatwal P, Haid S, Catanese M, Zeisel M, Nicosia A, Baumert T, Kaderali L, Pietschmann T. Role of the hypervariable region 1 (HVR1) for the interplay of hepatitis C virus with entry factors and lipoproteins. J. Virol., 2014, 88, 12644-55.

King LY, Johnson KB, Zheng H, Weil L, Gudewicz T, Hoshida T, Corey KE, Ajayi T, Ufere N, Baumert TF, Chan AT, Tarabe KK, Fuchs BC, Chung RT. Host genetics predict clinical deterioration in HCV related cirrhosis. PLoS One, 2014, 9(12):e114747 doi:10.1371/journal.pone.0114747.
Carbajo-Lozova J, Ma-Lauer Y, Malesevic M, Theuerkorn M, Kahlert V, Prell E, Von Brunn B, Muth D, Baumert TF, Drosten C, Fischer G, Von Brunn A. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus. Res., 2014, 184, 44-53.

Piardi T, Sommacale D, Baumert T, Mutter D, Marescaux J, Pessaux P. Laparoscopic resection for hepatocellular carcinoma: comparison between Middle Eastern and Western experience. Hepatobiliary Surg. Nutr., 2014, 3, 60-72.

 

Chung RT, Baumert TF. “Curing Chronic Hepatitis C — The Arc of a Medical Triumph. N. Engl. J. Med., 2014, 370, 1576-8.

Mailly L, Zeisel MB, Baumert TF. Genetically humanized mice recapitulate the entire hepatitis C virus life cycle. J. Hepatol., 2014, 60, 671-3.

Fauvelle C, Felmlee DJ, Baumert TF. Unraveling hepatitis C virus structure. Cell Res., 2014, 24, 385-6.

Verrier ER, Gack MU, Baumert TF. cGAS, innate immune responses and viral hepatitis. Hepatology, 2014, 60, 1098-100.

Tawar RG, Mailly L, Baumert TF. A new HCV mouse model on the block. Cell. Res., 2014, 24, 1153-4.

Baumert T, Fauvelle C, Chen D, Lauer GM. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J. Hepatol., 2014, 61(S1), S34-S44.

Felmlee DJ, Schuster C, Baumert TF. A new tool for the study of hepatitis C virus genotype 3 and its associated liver disease biology. Hepatology, 2014, 60, 1806-8.

Baumert TF, Zeuzem S. Overcoming the roadblocks in hepatitis C virus infection. J Hepatol., 2014, 61(1 Suppl), S1-2.

Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J. Hepatol., 2014, 61(1S):S79-S90.

Baumert TF, Meredith L, Ni Y, Felmlee DJ, McKeating JA, Urban S. Entry of hepatitis B and C viruses – recent progress and future impact. Curr. Opin. Virol., 2014, 4C, 58-65.

Zona L, Tawar RG, Zeisel MB, Xiao F, Schuster C, Lupberger J, Baumert TF. CD81-receptor associations – impact for hepatitis C virus entry and antiviral therapies. Viruses, 2014, 6, 875-92.

Fofana I, Jilg N, Chung RT, Baumert TF. Entry inhibitors and future treatment of hepatitis C. Antiviral Res., 2014, 104, 136-42.

Thimme R, Heim M, Baumert TF, Nassal M, Moradpour D. Hepatitis B and C: From Molecular virology to new antiviral therapies (part 1) Dtsch Med. Wochenschr., 2014, 139(13), 655-9.

Thimme R, Heim M, Baumert TF, Nassal M, Moradpour D. Hepatitis B and C: From Molecular virology to new antiviral therapies (part 2) Dtsch Med. Wochenschr., 2014, 139(15), 778-82.

Schaefer M, Sarkar R, Weich V, Effenberg S, Friebe A, Heinze L, Spengler U, Schläpfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T. Escitalopram for the prevention of peginterferon alpha-2a and ribavirin-associated depression in HCV-infected patients (The CIPPAD study). Annals of Internal Medicine, 2012, 157, 94-103.
Fofana I*, Fafi-Kremer S*, Carolla P*, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Hayer J, Combet C, Cosset FL, Pietschmann T, Hiet MS, Bartenschlager R, Habersetzer F, Doffoel M, Keck ZY, Foung SK, Zeisel MB, Stoll-Keller F, Baumert TF. Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology, 2012, 143, 223-233.e9. *Authors contributed equally.
Dill MT, Makowska Z, Duong FH, Merkofer F, Filipowicz M, Baumert TF, Tornillo L, Terracciano L, Heim MH. Interferon gamma stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology, 2012, 143, 777-786.
Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, Stamataki Z, Meredith LW, Rowe Ia, Luo G, Lopez-Ramirez MA, Baumert TF, Weksler B, Couraud PO, Kim KS, Romero IA, Jopling C, Morgello S, Balfe P, Mckeating JA. Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology, 2012, 142, 634-643.
Jo J, Bengsch B, Seigel B, Rau JS, Schmidt J, Bisse E, Aichele P, Aichele U, Joeckel L, Royer C, Sa Ferreira K, Borner C, Baumert TF, Blum HE, Lohmann V, Fischer R, Thimme R. Low perforin expression of early differentiated HCV-specific CD8+T cells limits their hepatotoxic potential. J. Hepatol., 2012, 57, 9-16.
Lacek K, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, Slowikowski MP, Fafi-Kremer S, Patel AH, Baumert TF, Folgori A, Leroux-Roels G, Cortese R, Meuleman P, Nicosia A. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J. Hepatol., 2012, 57, 17-23.
Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U. A new class of synthetic peptide inhibitors block attachment and entry of human pathogenic viruses. J. Infect. Dis., 2012, 205, 1654-64.
Florentin J, Aouar B, Dental C, Thumann C, Gondois-Rey F, Baumert TF, Dubreuil P, Nunes JA, Olive D, Hirsch I, Stranska R. HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells. Blood, 2012, 120, 4544-51.
Da Costa D*, Turek M*, Felmlee D*, Girardi E, Pfeffer S, Long G, Bartenschlager R, Zeisel MB#, Baumert TF#. Reconstitution of the entire hepatitis C virus life cycle in non-hepatic cells. J. Virol., 2012, 86, 11919-25. *Authors contributed equally, #authors contributed equally.
Molina-Jimenez F, Benedicto I, Loan Dao Thi V, Gondar V, Lavilette D, Marin JJG, Briz O, Moreno-Otero R, Aldabe R, Baumert TF, Cosset FL, Lopez-Cabrera M, Majano P. Matrigel-embedded 3D culture of Huh-7 cells as hepatocyte-like polarized system to study hepatitis C virus cycle. Virology, 2012, 425, 31-9.
Dental C, Florentin J, Aouar B, Gondois-Rey F, Durantel D, Baumert T, Nunes JA, Olive D, Hirsch I, Stranska R. Hepatitis C virus fails to activate NF-κB signaling in plasmacytoid dendritic cells. J. Virol., 2012, 86, 1090-6. (IF=4.64)
ACL 19. Farquhar M, Hu K, Harris HJ, Davis C, Brimacombe CL, Fletcher SJ, Baumert T, Rappoport JZ, Balfe P, Mckeating J. Hepatitis C virus induces CD81 and claudin-1 receptor endocytosis: a role in particle internalization. J. Virol., 2012, 86, 4305-16.
Dao Thi VL, Granier C, Zeisel MB, Guerin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M. Characterization of hepatitis C virus particle sub-populations reveals multiple usage of the scavenger receptor BI for entry steps. J. Biol. Chem., 2012, 287, 31242-57.
Guan M, Wang W, Liu X, Tong Y, Liu Y, Ren H, Zhu S, Dubuisson J, Baumert TF, Zhu Y, Peng H, Aurelian L, Zhao P, Qi Z. Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J. Biol. Chem., 2012, 287, 35631-45.
El-Andaloussi N, Bonifati S, Kaufmann JK, Mailly L, Daeffler L, Deryckère F, Nettelbeck DM, Rommelaere J, Marchini A. Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential. J. Virol., 2012, 86, 10418-31.

Lupberger J, Felmlee D, Baumert TF. Cholesterol uptake and hepatitis C virus entry. J. Hepatol., 2012, 57, 215-7.
Polyak SJ, Morishima C, Scott JD, Cox A, Stanislau E, Higgs M, Loo M, Mason LG, Lindenbach B, Baumert TF, Randall G, Pawlotsky JM, Gale M. A summary of the 18th International Symposium on Hepatitis C Virus and Related Viruses. Gastroenterology, 2012, 142, e1-5.
Barth H, Raghuraman S. Persistent infectious diseases say – IDO. Role of indoleamine-2-3-dioxygenase in disease pathogenesis and implications for therapy. Crit. Rev. Microbiol., 2012, 40, 360-8.
Lambotin M, Barth H, Moog C, Habersetzer F, Baumert TF, Stoll-Keller F, Fafi-Kremer S. Challenges for HCV vaccine development in HIV-HCV co-infection. Exp. Rev. Vaccines, 2012, 11, 791-804.
Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q, Fofana I, Heydmann L, Stoll-Keller F, Baumert TF. Neutralizing antibodies and pathogenesis of hepatitis C virus infection. Viruses, 2012, 4, 2016-30.
Habersetzer F, Leboeuf C, Doffoël M, Baumert TF. Boceprevir and personalized medicine in hepatitis C virus infection. Pharmacogenomics Pers. Med., 2012, 5, 125-137.

Lupberger J*, Zeisel MB*, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, Mckeating JA, Brino L, Baumert TF. EGFR and EphA2 are host factors for hepatitis C virus entry and targets for antiviral therapy. Nat. Med., 2011, 17, 589-95. *Authors contributed equally.

Barth H, Rybczynska J, Patient R, Choi Y, Sapp RK, Baumert TF, Krawczynski K, Liang TJ. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzee. Hepatology, 2011, 54, 1135-48.

Habersetzer F, Bain C, Toh L, Maynard-Muet M, Leroy V, Zarsky JP, Feray C, Baumert TF, Bronowicki JP, Doffoel M, Bonnefoy JY, Limacher JM, Trepo C, Inchauspe G, Honnet G. A poxvirus-based vaccine is safe and induces antiviral T cell responses with decrease of viral load in patients with chronic hepatitis C. Gastroenterology, 2011, 141, 890-99.

Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, Mckeating JA, Mckelvy J, Wong-Staal F. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J. Hepatol., 2011, 54, 48-55.

Ehrhardt M, Leidinger P, Keller A, Baumert T, Diez J, Meese E, Meyerhans A. Profound differences of microRNA expression patterns in hepatocytes and hepatoma cell lines commonly used in hepatitis C virus studies. Hepatology, 2011, 54, 1112-3.

Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, Mckeating JA. Neutralizing antibody resistant hepatitis C virus cell-to-cell transmission. J. Virol., 2011, 85, 596-605.

Laperche S, Bouchardeau F, Andre-Gamier E, Thibault V, Roque-Afonso AM, Trimoulet P, Colimon R, Duverlie G, Leguillou-Guillemette H, Lunel F, Bouvier-Alias M, Pawlotsky JM, Henquell C, Schvoerer E, Stoll-Keller F, Chaix ML, Branger M, Gaudy-Graffin C, Rosenberg AR, Pozzetto B, Vallet S, Baazia Y, Izopet J, Lefrere JJ. Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits. J. Clin. Microbiol., 2011, 49, 1113-5.

 

Barth H. Insights into the role of interferon lambda in hepatitis C virus infection. J. Hepatol., 2011, 54, 844-7.

Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J. Hepatol., 2011, 54, 566-76.

Schuster C, Lefèvre M, Baumert TF. Triglyceride synthesis and hepatitis C virus production – identification of a novel host factor as antiviral target. Hepatology, 2011, 53, 1046-8.

Robinet E, Baumert TF. A first step towards a mouse model for hepatitis C virus infection containing a human immune system. J. Hepatol., 2011, 55, 718-20.

Zeisel MB, Da Costa D, Baumert TF. Opening the door to hepatitis C virus infection in genetically humanized mice. Hepatology, 2011, 54, 1873-5.

Turek M, Lupberger J, Baumert TF, Zeisel MB. Sésame, ouvre-toi : régulation de l’entrée du virus de l’hépatite C. Médecine Science, 2011, 27, 929-31.

Benga W.J., Krieger S. E., Dimitrova M., Zeisel M.B., Parnot M., Lupberger J., Hildt E., Luo G., Mclauchlan J., Baumert T.F., Schuster C. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology, 2010, 51, 43-53.

Krieger S.E., Zeisel M.B., Davis C., Thumann C., Harris H.J., Schnober E.K., Mee C., Soulier E., Royer C., Lambotin M., Grunert F., Thi V.L.D., Dreux M., Cosset F.L., Mckeating Jane A., Schuster C., Baumert T.F. Inhibition of hepatitis C virus infection by anti-Claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology, 2010, 51, 1144-57.

Keymeulen B., Candon S., Fafi-Kremer S., Ziegler A., Leruez-Ville M., Mathieu C., Vandemeulebroucke E., Walter M., Crenier L., Thervet E., Legendre C., Pierard D., Hale G., Waldmann H., Bach J.F., Seigneurin J.M., Pipeleers D., Chatenoud L. Transient Epstein Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood, 2010, 115, 1145-55.

Marmier-Savet C., Larosa F., Legrand F., Witz B., Michallet M., Ranta D., Louvat P., Puyraveau M., Raus N., Tavernier M., Mathieu-Nafissi S., Hequet O., Pallandre J.R., Vitte F., Collonge-Rame M.A., Pouthier F., Bresson J.L., Deconinck E., Tiberghien P., Robinet E. G-C SF-induced anenploidy does not affect CD34+ cells and does not require cell division. Blood, 2010, 115, 910-1.

Dhillon S., Witteveldt J., Gatherer D., Owsianka A.M., Zeisel M.B., Zahid M.N., Rycklowska M., Foung S.K., Baumert T.F., Angus A.G.N., Patel A.H. Mutations within a conserved region of the Hepatitis C virus E2 glycoprotein that influence virus receptor interactions and sensitivity to neutralizing antibodies. J. Virol., 2010, 84, 5494-507.

Kremer S., Martern J.F., Bilger K., Lioure B., Fornecker Y., Stoll-Keller F., Namer I.J., Dietemann J.L., Fafi-Kremer S. EBV limbic encephalitis after allogenic hematopoietic stem cell transplantation. J. Neuroradiol., 2010, 37, 189-91.

Holl V., Xu K., Peressin M., Lederle A., Biedma M.E., Delaporte M., Decoville T., Schmidt S., Laumond G., Aubertin A.M., Moog C. Stimulation of HIV-1 replication in immature dendritic cells in contact with primary CD4 T-or B-lymphocytes. J. Virol., 2010, 84, 4172-82.

Bankwitz D., Steinmann E., Bitzegeio J., Ciesek S., Friesland M., Hermann E., Zeisel M.B., Baumert T.F., Keck Z.Y., Foung S.K., Pécheur E.I., Pietschmann T. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site and protects conserved neutralizing epitopes. J. Virol., 2010, 84, 5751-63.

Bitzegeio J., Bankwitz D., Hüging K., Haid S., Brohm C., Zeisel M.B., Herrmann E., Iken M., Ott M., Baumert T.F., Pietschmann T. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathogens, 2010, 6:e1000978.

Bouzgarrou N., Hassen E., Gabbouj S., Schvoerer E., Ben Mami N., Triki H., Chouchane L. Lack of effect of tumor necrosis factor-alpha-308 G/A polymorphism on severity of liver fibrosis in Tunisian hepatitis C virus (HCV)-infected patients. Gastroentérol. Clin. Biol., 2010, 34, 297-304.

Fletcher N., Yang J.P., Farquhar M., Hu K., He Q., Dowd K., Ray S., Krieger S., Baumert T., Balfe P., Mckeating J.A., Wong-Staal F. Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology, 2010, 139, 1365-74.

Lambotin M., Baumert T.F., Barth H. Distinct intracellular trafficking of hepatitis C virus in myeloid and plasmacytoid dendritic cells. J. Virol., 2010, 84, 8964-9.

Fafi-Kremer S., Fofana I., Soulier E., Carolla P., Meuleman P., Leroux-Roels G., Patel A.H., Cosset F.L., Pessaux P., Doffoël M., Wolf P., Stoll-Keller F., Baumert T.F. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J. Exp. Med., 2010, 207, 2019-31.

Fofana I., Krieger S.E., Grunert F., Glauben S., Xiao F., Fafi-Kremer S., Soulier E., Royer C., Thumann C., Mee C.J., Mckeating J.A., Dragic T., Pessaux P., Stoll-Keller F., Schuster C., Thompson J., Baumert T.F. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology, 2010, 139, 953-964.

Henry C., Deschamps M., Rohrlich P.S., Pallandre J.R., Remy-Martin J.P., Callanan M., Traverse-Glehen A., Grandclement C., Garnache-Ottou F., Gressin R., Deconinck E., Salles G., Robinet E., Tiberghien P., Borg C., Ferrand C. Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance. Blood, 2010, 115, 2420-9.

Hishiki T., Shimizu Y., Tobita R., Sugiyama K., Ogawa K., Funami K., Ohsaki Y., Fujimoto T., Takaku H., Wakita T., Baumert T.F., Miyanari Y., Shimotohno K. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J. Virol., 2010, 84, 12048-57.

Imperiale A., Greget M., Chabrier G., Keomany J., Rust E., Detour J., Pessaux P., Goichot B. Solitary hepatic metastasis from medullary thyroid carcinoma mimicking atypical hemangioma: insights from multimodality diagnostic approach by MRI, F-18 FDG and F-18 FDOPA PET/CT. Clin. Nucl. Med., 2010, 35, 434-7.

Mahfud M., Breitenstein S., El-Badry A.M., Puhan M., Rickenbacher A., Samaras P., Pessaux P., Lopez-Ben S., Jaeck D., Figueras J., Alain-Clavien P. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J. Surg., 2010, 34, 92-100.

Ntourakis D., Marzano E., Lopez Penza P.A., Bachellier P., Jaeck D., Pessaux P. Robotic distal splenopancreatectomy: bridging the gap between pancreatic and minimal access surgery. J. Gastrointest. Surg., 2010, 14, 1326-30.

Pessaux P., Marzano E., Casnedi S., Bachellier P., Jaeck D., Chenard M.P. Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study. World J. Surg., 2010, 34, 2765-72.

Pessaux P., Marzano E., Rosso E. A plea for the artery-first dissection during pancreaticoduodenectomy. J. Am. Coll. Surg., 2010, 211, 142-3.

Ridereau-Zins C., Aube C., Luet D., Vielle B., Pilleul F., Dumortier J., Gandon Y., Heresbach D., Beziat C., Bailly F., Debilly M., Carbonnel F., Pierredon-Foulongne M.A., Bismuth M., Chretien J.M., Lebigot J., Pessaux P., Valette P.J. Assessment of water enema computed tomography: an effective imaging technique for the diagnosis of colon cancer: Colon cancer: computed tomography using a water enema. Abdom. Imaging, 2010, 35, 407-13.

Marmier-Savet C., Larosa F., Legrand F., Witz B., Michallet M., Ranta D., Louvat P., Puyraveau M., Pouthier F., Deconinck E., Tiberghien P., Robinet E. Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors. Transfusion, 2010, 50, 2676-85.

 

Lambotin M., Raghuraman S., Stoll-Keller F., Baumert T.F., Barth H. A look behind closed doors: Interaction of persistent viruses with dendritic cells. Nat. Rev. Microbiol., 2010, 8, 350-60.

Redel L., Le Douce V., Cherrier T., Marban C., Janossy A., Aunis D., Van Lint C., Rohr O., Schwartz C. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes. J. Leukoc., Biol., 2010, 87, 575-88.

Pfeffer S., Baumert T.F. Antagonizing microRNA-122 and treatment of hepatitis C virus infection. Hepatology, 2010, 51, 1461-3.

Georgel P., Schuster C., Zeisel M.B., Stoll-Keller F., Berg T., Bahram S., Baumert T.F. Virus-host interactions in hepatitis C virus infection – implications for molecular pathogenesis and antiviral strategies. Trends in Molecular Medicine, 2010, 16, 277-86.

Robinet E., Baumert T.F. Host and viral determinants for engraftment of virus permissive human hepatocytes into chimeric immunodeficient mice. J. Hepatol., 2010, 53, 421-3.

Zeisel M.B., Turek M., Baumert T.F. Getting closer to the patient: Upgrade of hepatitis C virus infection in primary human hepatocytes. J. Hepatol., 2010, 53, 388-9.

Mailly L., Le Boeuf C., Tiberghien P., Baumert T.F., Robinet E. Genetically engineered T-cells expressing a gancyclovir-sensitive HSV-TK suicide gene for the prevention of graft versus host disease. Current Opinion in Investigational Drugs, 2010, 11, 559-70.

Moenne-Loccoz R., Razafinjatovo R., Habersetzer F., Ananna A., Doffoel M., Wolf P., Gut J.P., Baumert T., Stoll-Keller F., Schvoerer E. Tropism of hepatitis C virus for leukocytes importance of the analysis of viral E1 and E2 envelope glycoprotein genes by sequencing. Pathol. Biol., 2010, 58, 170-4.

Zeisel M.B., Turek M., Baumert T.F. Impact of tight junction proteins for hepatitis C virus entry. Future Virology, 2010, 5, 263-271.

Pfeffer S., Baumert T.F.  Impact of microRNAs for pathogenesis and treatment of hepatitis C virus infection. Gastroentérologie Clinique et Biologique, 2010, 34, 431-5.

Fafi-Kremer S., Habersetzer F., Baumert T.F. Hepatitis C virus entry and glucocorticosteroids. J. Hepatol., 2010, 53, 1148-50.

Henry C., Ramadan A., Montcuquet N., Pallandre J.R., Mercier-Letondal P., Deschamps M., Tiberghien P., Ferrand C., Robinet E. CD3+CD20+ cells may be an artifact of flow cytometry: comment on the article by Wilk et al. Arthritis Rheum., 2010, 62, 2561-3.

Vieyres G., Angus A.G., Haberstroh A., Baumert T.F., Dubuisson J., Patel A.H. Rapid synchronization of Hepatitis C Virus infection by magnetic adsorption. J. Virol. Methods., 2009, 157, 69-79.

Tian Z.F., Shen H., Fu X.H., Chen Y.C., Blum H.E., Baumert T.F., Zhao X.P. Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81. World. J. Gastroenterol., 2009, 15, 240-4.

Pastor R., Habersetzer F., Fafi-Kremer S., Doffoel M., Baumert T.F., Gut J.P., Stoll-Keller F., Schvoerer E. Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment naïve patients. World. J. Gastroenterol., 2009, 15, 753-5.

Sava I.G., Zhang F., Toma I., Theilacker C., Li B., Baumert T.F., Holst O., Linhardt R.J., Huebner J. Novel interactions of glycosaminoglycans and bacterial glycolipids mediate binding of enterococci to human cells. J. Biol. Chem., 2009, 284, 18194-201.

Gondois-Rey F., Dental C., Halfon P., Baumert T.F., Olive D., Hirsch I. Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS ONE, 2009, 4, e4319.

Weseslindtner L., Neumann-Haefelin C., Viazov S., Haberstroh A., Kletzmayr J., Aberle J.H., Timm J., Ross S.R., Klauser-Braun R., Baumert T.F., Roggendorf M., Thimme R., Holzmann H. Acute infection with a single hepatitis C virus strain in dialysis patients: Analysis of adaptive immune response and viral variability. J. Hepatol., 2009, 50, 693-704.

Hoffmann M., Zeisel M.B., Jilg N., Paranhos-Baccala G., Stoll-Keller F., Wakita T., Hafkemeyer P., Blum H.E., Barth H., Henneke P., Baumert T.F. Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles. J. Innate Immun., 2009, 1, 446-454.

Mello I.M., Thumann C., Schvoerer E., Soulier E., Pinho J.R., Silvestre D.A., Queiroz A.T., Wolf P., Baumert T.F., Stoll-Keller F., Pereira C.A. Conservation of hepatitis C virus non-structural protein 3 amino acid sequence in viral isolates during liver transplantation. J. Viral. Hepat., 2009, 16, 732-7.

Amiel C., Legoff J., Lescure F.X., Coste-Burel M., Deback C., Fafi-Kremer S., Gueudin M., Lafon M.E., Leruez-Ville M., Mengelle C., Payan C., Pillet S. Epstein-Barr virus load in whole blood correlates with HIV surrogate markers and lymphoma: a French national cross-sectional study. J. Acquir. Immune Defic. Syndr., 2009, 50, 427-9.

Kremer S., Matern J.F., Bilger K., Lioure B., Fornecker Y., Stoll-Keller F., Namer I.J., Dieteman J.L., Fafi-Kremer S. EBV limbic encephalitis after allogenic hematopoietic stem cell transplantation. J. Neuroradiol., 2009, 37, 189-91.

Reuse S., Calao M., Kabeya K., Guiguen A., Gatot J.S., Quivy V., Vanhulle C., Lamine A., Vaira D., Demonte D., Martinelli V., Veithen E., Cherrier T., Avettand V., Poutrel S., Piette J., De Launoit Y., Moutschen M., Burny A., Rouzioux C., De Wit S., Herbein G., Rohr O., Collette Y., Lambotte O., Clumeck N., Van Lint C. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostatin: implications for treatment of latent infection. PLoS One, 2009, 4, e6093.

Himmelsbach K., Sauter D., Baumert T., Ludwig L., Blum H., Hildt E. New aspects of an anti-tumor drug: sorafenib efficiently inhibits HCV replication. Gut, 2009, 58, 1644-53.

Cherrier T., Suzanne S., Redel L., Calao M., Marban C., Samah B., Mukerjee R., Schwartz C., Gras G., Sawaya B.E., Zeichner S.L., Aunis D., Van Lint C., Rohr O. p21 (WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1. Oncogène, 2009, 28, 3380-9.

Fenyö E.M., Heath A., Dispinseri S., Holmes H., Lusso P., Zolla-Pazner S., Donners H., Heyndrickx L., Alcami J., Bongertz V., Jassoy C., Malnati M., Montefiori D., Moog C., Morris L., Osmanov S., Polonis V., Sattentau Q., Schuitemaker H., Sutthent R., Wrin T., Scarlatti G. International Network for Comparison of HIV Neutralization Assays: The NeutNet Report. PLoS One, 2009, 4:e4505.

Lambotte O., Ferrari G., Moog C., Venet A., Yates N.L., Liao H-X, Parks R., Hicks C.B., Tomaras G., Montefiori D., Haynes B.F., Delfraissy J.F. Heterogeneous neutralizing antibody and Antibody-Dependent Cell Cytotoxicity responses in HIV-1 Elite Controllers, AIDS, 2009, 15, 897-906.

Tudor D., Derrien M., Diomede L., Drillet A.S., Houimel M., Moog C., Reynes J.M., Lopalco L., Bomsel M. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol., 2009, 2, 412-26.

Perez-Anes A., Spataro G., Coppel Y., Moog C., Blanzat M., Turrin C., Caminade A., Lattes I.R., Majoral J.P. Phosphonate terminated PPH dendrimers: influence of pendant alkyl chains on the in vitro anti-HIV-1 properties. Org. Biomol. Chem., 2009, 7, 3491-3498.

Corellou F., Schwartz C., Motta J.P., Djouani-Tahri E.B., Sanchez F., Bouget F.Y. Clocks in the Green Lineage: Comparative Functional Analysis of the Circadian Architecture of the Picoeukaryote Ostreococcus. Plant Cell., 2009, 21, 3436-49.

Legrand-Abravanel F., Colson P., Leguillou-Guillemette H., Alric L., Ravaux I., Lunel-Fabiani F., Bouviers-Alias M., Trimoulet P., Chaix M.L., Hezode C., Foucher J., Fontaine H., Roque-Afonso A.M., Gassin M., Schvoerer E., Gaudy C., Roche B., Doffoel M., D’alteroche L., Vallet S., Baazia Y., Pozzetto B., Thibault V., Nousbaum J.B., Roulot D., Coppere H., Poinard T., Payan C., Izopet J. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J. Med. Virol., 2009, 81, 2029-35.

Bouzgarrou N., Hassen E., Mahfoudh W., Gabbouj S., Schvoerer E., Ben Yahia A., Ben Mami N., Triki H., Chouchane L. NS5A (ISDR-V3) region genetic variability of Tunisian HCV-1b strains: correlation with the response to the combined interferon/ribavirin therapy. J. Med. Virol., 2009, 81, 2021-8.

Brehant O., Pessaux P., Regenet N., Tuech J.J., Panaro F., Mantion G., Tassetti V., Lehur P.A., Arnaud J.P. Healing of stoma orifices: multicenter, prospective, randomized study comparing calcium alginate mesh and polyvidone iodine mesh. World J. Surg., 2009, 33, 1795-801.

Oussoultzoglou E., Romain B., Panaro F., Rosso E., Pessaux P., Bachellier P., Jaeck D. Long-term survival after liver resection for colorectal liver metastases in patients with hepatic pedicle lymph nodes involvement in the era of new chemotherapy regimens. Ann. Surg., 2009, 249, 879-86.

Pessaux P., Panaro F. Advantages of the first-step totally laparoscopic approach in 2-staged hepatectomy for colorectal synchronous liver metastasis. Surgery, 2009, 145, 453.

Zacharias T., Oussoultzoglou E., Jaeck D., Pessaux P., Bachellier P. Surgery for recurrence of periampullary malignancies. J. Gastrointest. Surg., 2009, 13, 760-7.

 

Schuster C., Baumert T.F. EWI-2wint-A host cell factor inhibiting hepatitis C virus entry. J. Hepatol., 2009, 50, 222-4.

Stoll-Keller F., Barth H., Fafi-Kremer S., Zeisel M.B., Baumert T.F. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev. Vaccines, 2009, 8, 333-45.

Zeisel M.B., Barth H., Schuster C., Baumert T.F. Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Frontiers in Biosciences, 2009, 14, 3274-85.

Lambotin M., Stoll-Keller F., Baumert T.F. Host responses to hepatitis C virus infection: gene expression profiles and viral pathogenesis. In: “Host Gene Responses to RNA Viral Infection“, (D. Yang ed.), Word Scientific Publishing New Jersey, 2009, p.471-494.

Pfeffer S., Baumert T.F. Unravelling the importance of microRNAs during hepatitis C virus infection in the human liver. J. Hepatol., 2009, 51, 606-9.

Zeisel M.B., Baumert T.F. HCV entry and neutralizing antibodies: lessons from viral variants. Future Microbiol., 2009, 4, 511-7.

Eyre N.S., Baumert T.F., Beard M.R. Closing the gap: the tight junction protein occluding and hepatitis C virus entry. Hepatology, 2009, 49, 1770-2.

Habersetzer F., Baumert T.F., Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr. Opin. Mol. Ther., 2009, 11, 456-62.

Zeisel M.B., Fafi-Kremer S., Robinet E., Habersetzer F., Baumert T.F., Stoll-Keller F. Adaptive Immunity to hepatitis C virus. Viruses, 2009, 1, 276-297.

Forthall D., Moog C. Fc receptor-mediated antiviral antibodies. Current opinion in HIV and AIDS, 2009, 4, 388-393.

Schvoerer E., Gut J.P., Stoll-Keller F. Effets des changements climatiques sur les maladies virales : quels sont les risques potentiels ? Virologie – Revue française des enseignants de virologie. 2009, 13, 1-6.

Holl V., Peressin M., Moog C. Antibody mediated Fcg receptor-based mechanisms of HIV inhibition: Recent findings and new vaccination strategies. Viruses, 2009, 1, 1265-1294.

Barth H., Schnober E.K., Neumann-Haefelin C., Thumann C., Zeisel M.B., Diepolder H.M., Hu Z., Liang T.J., Blum H.E., Thimme R., Lambotin M., Baumert T.F. Scavenger receptor Class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J. Virol., 2008, 82, 3466-79.

Wolf M., Dimitrova M., Baumert T.F., Schuster C. The major form of hepatitis C virus alternate reading frame protein is suppressed by core protein expression. Nucleic Acids Res., 2008, 36, 3054-64.

Meyer F., Dimitrova M., Jedrzejenska J., Arntz Y., Schaaf P., Frisch B., Voegel J.C., Ogier J. Relevance of bi-functionalized polyelectrolyte multilayers for cell transfection. Biomaterials., 2008, 29, 618-24.

Hafkemeyer P., Brinkmann U., Brinkmann E., Pastan I., Blum H. E., Baumert T.F. Pseudomonas exotoxin antisense RNA selectively kills hepatitis B virus infected cells. World J. Gastroenterol., 2008, 14, 2810-7.

Deschamps M., Robinet E. , Certoux J.M., Mercier P., Sauce D., De Vos J., Montcuquet N., Bonyhadi M., Reme T., Tiberghien P., Ferrand C. Transcriptome of retrovirally transduced CD8(+) lymphocytes: Influence of cell activation, transgene integration, and selection process. Mol. Immunol., 2008, 45, 1112-25.

Fafi-Kremer S., Morand P., Barranger C., Bargues G., Magro S., Bes J., Bourgeois P., Joannes M., Seigneurin J.M. Evaluation of the Epstein-Barr Virus R-Gene Quantification Kit in Whole Blood with different Extraction Methods and PCR Platforms. J. Mol. Diag., 2008, 10, 78-84.

Mercier-Letondal P., Montcuquet N., Sauce D., Certoux J.M., Jeanningros S., Ferrand C., Bonyhadi M., Tiberghien P., Robinet E. Alloreactivity of ex vivo-expanded T cells is correlated with expansion and CD4/CD8 ratio. Cytotherapy, 2008, 10, 275-88.

Bennour E., Ferrand C., Remy-Martin J.P., Certoux J.M., Gorke S., Qasim W., Gaspar B., Baumert T.F., Duperrier A., Deschamps M., Fehse B., Tiberghien P., Robinet E. Abnormal expression of the only CD34 part of a transgenic CD 34/Herpes Simplex Virus-thymidine kinase fusion protein is associated with ganciclovir resistance. Hum. Gene Ther., 2008, 19, 699-709.

Bouzgarrou N., Hassen E., Schvoerer E., Stoll-Keller F., Bahri O., Chikh I., Maamouri N., Mammi N., Saffar H., Triki H., Chouchane L. Association of Interleukin-18 polymorphisms and plasma level with outcome of chronic HCV infection. J. Med. Virol., 2008, 80, 607-14.

Thumann C., Schvoerer E., Abraham J.D., Bohbot A., Stoll-Keller F., Aubertin A.M., Kieny M.P. Hepatitis C virus structural proteins do not prevent human dendritic cell maturation. Gastroentérol. Clin. Biol., 2008, 32, 59-68.

Espuelas S., Thumann C., Heurtault B., Schuber F., Frisch B. Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. Bioconjug. Chem., 2008, 19, 2385-93.

Lan L., Gorke S., Rau S.J., Zeisel M.B., Hildt E., Himmelsbach K., Carvajal-Yepes M., Huber R., Wakita T., Schmitt-Graeff A., Royer C., Blum H.E., Fischer R., Baumert T.F. Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J. Immunol., 2008, 181, 4926-35.

Mercier-Letondal P., Deschamps M., Sauce D., Certoux J.M., Milpied N., Lioure B., Cahn J.Y., Deconinck E., Ferrand C., Tigerghien P., Robinet E. Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response? Hum. Gen. Ther., 2008, 19, 937-50.

Imbert I., Snijder E.J., Dimitrova M., Guillemot J.C., Lecine P., Carnard B. The SARS-Coronavirus PLnc domain of nsp3 as a replication/transcription scaffolding protein. Virus Res., 2008, 133, 136-48.

Morand P., Fafi-Kremer S., Mansuy L., Schmitt E., Weinbreck N., Kremer S. Neuroimaging of Epstein-Barr Virus Infections in Children. Pediatr. Radiol., 2008, 38, 354-5.

Haberstroh A., Schnober E.K., Zeisel M.B., Carolla P., Barth H., Blum H.E., Cosset F.L., Koutsoudakis G., Bartenschlager R., Union A., Depla E., Owsianka A., Patel A.H., Schuster C., Stoll-Keller F., Doffoel M., Dreux M., Baumert T.F. Neutralizing host responses in hepatitis C virus infection target viral entry at post binding steps and membrane fusion. Gastroenterology, 2008, 135, 1719-1728.

Dimitrova M., Affolter C., Meyer F., Nguyen I., Richard D.G., Schuster C., Bartenschlager R., Voegel J.C., Ogier J., Baumert T.F. Sustained delivery of siRNAs targeting viral infection by cell-degradable multilayered polyelectrolyte films. Proc. Natl. Acad. Sci., USA, 2008, 105, 16320-16325.

Schramm F., Soulier E., Royer C., Weitten T., Fafi-Kremer S., Brignon N., Meyer N., Ellero B., Woehl-Jaegle M.L., Meyer C., Wolf P., Doffoel M., Baumert T.F., Stoll-Keller F., Schvoerer E. Frequent compartmentalization of hepatitis C virus with leukocyte-related amino acids in teh setting of liver transplantation. J. Infect. Dis., 2008, 198, 1656-1666.

Montcuquet N., Mercier-Letondal P., Perruche S., Duperrier A., Couturier M., Bouchekioua A., Bonyhadi M., Ferrand C., Tiberghien P., Robinet E. Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells. Immunology, 2008, 125, 320-30.

Fuks D., Pessaux P., Tuech J.J., Mauvais F., Bréhant O., Dumont F., Chatelain D., Yzet T., Joly J.P., Lefebure B., Deshpande S., Arnaud J.P., Verhaeghe P., Regimbeau J.M. Management of patients with carcinoma of the right colon invading the duodenum or pancreatic head. Int. J. Colorectal. Dis., 2008, 23, 477-81.

Kato T., Choi Y., Elmowalid G., Sapp R., Barth H., Furusaka A., Mishiro S., Wakita T., Krawczynski K., Liang T.J. Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenecity and emergence of an adaptive mutation. Hepatology, 2008, 48, 732-40.

Lermite E., Pessaux P., Teyssedou C., Etienne S., Brehant O., Arnaud J.P. Effect of preoperative endoscopic biliary drainage on infectious morbidity after pancreatoduodenectomy: a case-control study. Am. J. Surg., 2008, 195, 442-6.

Oussoultzoglou E., Panaro F., Rosso E., Zeca I., Bachellier P., Pessaux P., Jaeck D. Use of BiClamp decreased the severity of hypocalcemia after total thyroidectomy compared with LigaSure: a prospective study. World J. Surg., 2008, 32, 1968-73.

Oussoultzoglou E., Rosso E., Fuchshuber P., Stefanescu V., Diop B., Giraudo G., Pessaux P., Bachellier P., Jaeck D. Perioperative carcinoembryonic antigen measurements to predict curability after liver resection for colorectal metastases: a prospective study. Arch. Surg., 2008, 143, 1150-8.

Paulet E., Aube C., Pessaux P., Lebigot J., Lhermitte E., Oberti F., Ponthieux A., Cales P., Ridereau-Zins C., Pereira P.L. Factors limiting complete tumor ablation by radiofrequency ablation. Cardiovasc. Intervent. Radiol., 2008, 31, 107-15.

Stöhr S.W., Barber T., Bart P.A., Harari A., Moog C., Ciuffreda D., Cellerai C., Cowen M., Gamboni R., Burnet S., Legg K., Brodnicki E., Wolf H., Wagner R., Heeney J., Frachette M.J., Tartaglia J., Babiker A., Pantaleo G., Weber J. EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine, 2008 26, 3162-3174.

Harari A., Bart P.A., Stöhr W., Tapia G., Garcia M., Medjitna-Rais E., Burnet S., Cellerai C., Erlwein O., Barber T., Moog C., Liljestrom P., Wagner R., Wolf H., Kraehenbuhl M., Esteban J., Heeney M.J., Frachette J., Tartaglia S., Mccormack J.P., Babiker A., Weber J., Pantaleo G. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med., 2008, 205, 63-77.

Collette S., Bonnetain F., Paoletti X., Doffoel M., Bouche O., Raoul J.L., Rougier P., Masskouri F., Bedenne L., Barbare J. Prognosis of advanced hepatocellular carcinoma : comparison of 3 staging systems in two French clinical trials. Ann. Oncology, 2008, 19, 1117-26.

Doffoel M., Bouche O., Vetter D., Abergel A., Fratte S., Grange J.D., Stremsdoerfer N., Blanchi A., Bronowicki J.P., Caroli-Bosc F.X., Causse X., Masskouri F., Rougier P., Bedenne L. (Fédération Francophone de Cancérologie Digestive (FFCD 9402). Multicenter randomized phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolization for unresectable hepatocellular carcinoma in cirrhotic patients. Eur. J. Cancer, 2008, 44, 528-38.

Bonnetain F., Paoletti X., Colette S., Doffoel M., Bouche O., Raoul J.L., Rougier P., Masskouri F., Barbare J.C., Bedenne L. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma : results from two French clinical trials. Qual. Life Res., 2008, 17, 831-843.

 

Fafi-Kremer S., Stoll-Keller F., Baumert T.F. Efficient postexposure prophylaxis by hepatitis A vaccine. Hepatology, 2008, 47, 1416-8.

Barth H., Robinet E., Liang T.J., Baumert T.F. Mouse models for the study of HCV infection and virus-host interactions. J. Hepatol., 2008, 49, 134-42.

Zeisel M.B., Cosset F.L., Baumert T.F. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology, 2008, 48, 299-307.

Fafi-Kremer S., Zeisel M.B., Schvoerer E., Soulier E., Habersetzer F., Wolf P., Doffoel M., Baumert T.F., Stoll-Keller F. Neutralizing antibodies in hepatitis C virus infection. Gastroentérol. Clin. Biol., 2008, 32, 491-8.

Lupberger J., Brino L., Baumert T.F. RNAi – a powerful tool to unravel hepatitis C virus-host interactions within the infectious life cycle. J. Hepatol., 2008, 48, 523-5.

Lupberger J., Zeisel M.B., Haberstroh A., Schnober E.K., Krieger S., Soulier E., Thumann C., Royer C., Fafi-Kremer S., Schuster C., Stoll-Keller F., Blum H.E., Baumert T.F. Virus-host interactions during hepatitis C virus entry – Implications for pathogenesis and novel treatment approaches. In: “Virologica Sinica”, (X. Chen, M. Lu and D. Yang eds.), 2008, 22, 124-131.

Schramm F., Moenne-Loccoz R., Fafi-Kremer S., Soulier E., Royer C., Brignon N., Ellero B., Woehl-Jaegle M.L., Meyer C., Wolf P., Doffoel M., Gut J.P., Baumert T.F., Stoll-Keller F., Schvoerer E. Study of hepatitis C virus leukotropism by characterization of viral quasispecies in the liver transplantation setting. Pathol. Biol., 2008, 56, 487-491.

Schvoerer E., Massue J.P., Gut J.P., Stoll-Keller F. Climate change: impact on viral diseases. The Open Epidemiology Journal, 2008, 1, 45-48.

Stoll-Keller F., Fafi-Kremer S., Wolf P., Doffoel M., Baumert T. Novel strategies for preventing viral hepatitis C recurrence after liver transplantation. Bull. Acad. Natl. Med., 2008, 192, 1657-67.

Moog C. Immune responses that correlate with HIV-1 protection? AIDS, 2008, 22, 1461-2.

Zarski J.P., Doffoel M., Filoche B., Marcellin P., Samuel D., Bedossa P. Hepatitis C, cirrhosis and hepatocellular carcinoma. Gastroenterol. Clin. Biol., 2008, 32, S117-20.

Pestka J.M., Zeisel M.B., Bläser E., Schürmann P., Bartosch B., Cosset F.L., Patel H., Meisel H., Baumert J., Viazov S., Rispeter K., Blum H.E., Roggendorf M., Baumert T.F. Rapid induction of virus neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA, 2007, 104, 6025-6030.

Baumert T.F., Rosler C., Malim M., Weizsacker F. Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC 3C. Hepatology, 2007, 46, 682-689.

Lucas M., Ulsenheimer A., Pfafferot G., Heeg M.H.J., Gaudieri S., Gruner N., Rauch A., Gerlach J.T., Jung M.C., Zachoval R., Pape G.R., Santantonio T., Nitschko H., Obermeier M., Phillips R., Scriba T.J., Semmo N., Day C., Weber J.N., Fidler S., Thimme R., Haberstroh A., Baumert T.F., Klenerman P., Diepolder H.M. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS ONE, 2007, Jul 25, 2:e649.

Schvoerer E., Soulier E., Royer C., Renaudin A.C., Thumann C., Fafi-Kremer S., Brignon N., Doridot S., Meyer N., Ellero B., Woehl-Jaegle M.L., Meyer C., Wolf P., Zachary P., Baumert T.F., Stoll-Keller F. Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease. J. Infect. Dis., 2007, 196, 528-536.

Elmowalid G., Qiao M., Jeong S., Baumert T.F., Sapp R., Hu Z., Murthy K., Liang T.J. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl. Acad. Sci. USA, 2007, 104, 8427-32.

Kapadia S.B., Barth H., Baumert T.F., Mckeating J.A., Chisari F.V. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J. Virol., 2007, 81, 374-383.

Zeisel M.B., Koutsoudakis G., Schnober E.K., Haberstroh A., Blum H.E., Cosset F.L., Wakita T., Jaeck D., Doffoel M., Royer C., Soulier E., Schvoerer E., Schuster C., Stoll-Keller F., Pietschmann T., Bartenschlager R., Barth H., Baumert T.F. Scavenger receptor class B type I is a key host factor for hepatitis C virus required for an entry step closely linked to CD81. Hepatology, 2007, 46, 1722-1731.

Akazawa D., Date T., Morikawa K., Murayama A., Miyamoto M., Kaga M., Barth H., Baumert T.F., Dubuisson J., Wakita T. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J. Virol., 2007, 81, 5036-45.

Ballout M., Germi R., Fafi-Kremer S., Guimet J., Bargues G., Seigneurin J.M., Morand P. Real-time quantitative PCR for assessment of antiviral drug effets against Epstein-Barr virus replication and EBV late mRNA expression. J. Virol. Methods, 2007, 143, 38-44.

Payan C., Pivert A., Morand P., Fafi-Kremer S., Carrat F., Pol S., Cacoub P., Perronne C., Lunel F., ANRS HC02 RIBAVIC study team. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients. Gut, 2007, 58, 1111-1116.

Dimitrova M., Arntz Y., Lavalle P., Meyer F., Wolf M., Schuster C., Haikel Y., Voegel J.C., Ogier J. Adenoviral gene delivery from multilayered polyelectrolyte architectures. Adv. Funct. Mat., 2007, 17, 233-245.

Lapierre V., Auperin A., Robinet E., Ferrand C., Oubouzar N., Tramalloni D., Saas P., Debaene B., Lasser P., Tiberghien P. Immune modulation and microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer patients: results of a randomized study. Transfusion, 2007, 47, 1691-1699.

Nousbaum J.B., Cadranel J.F., Nahon P., Khac E.N., Moreau R., Thevenot T., Silvain C., Bureau C., Nouel O., Pilette C., Paupard T., Vanbiervliet G., Oberti F., Davion T., Jouannaud V., Roche B., Bernard P.H., Beaulieu S., Danne O., Thabut D., Chagneau-Derrode C., De Ledinghen V., Mathurin P., Pauwels A., Bronowicki J.P., Habersetzer F., Abergel A., Audigier J.C., Sapey T., Grange J.D., Tran A. Club Francophone pour l’Etude de l’Hypertension Portale ; Association Nationale des Hépato-Gastroentérologues des Hôpitaux Généraux de France. Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology, 2007, 45, 1275-81.

Deschamps M., Mercier P., Certoux J.M., Henry C., Lioure B., Pagneux C., Cahn J.Y., Deconinck E., Tiberghien P., Robinet E., Ferrand C. Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T-cells infused with a hematopoietic graft. Blood, 2007, 110, 3842-52. ;

Dumortier J., Mekki Y., Rimmele T., Ber C., Maillard E., Fafi-Kremer S., Lina B., Scoazec J.Y., Delafosse B., Boillot O. EBV-induced fulminant hepatic failure: favourable outcome after liver transplantation. Gastroenterol. Clin. Biol., 2007., 31, 725-8.

Laperche S., Bouchardeau F., Thibault V., Pozzeto B., Vallet S., Rosenberg A.R., Roque-Afonso A.M., Gassin M., Stoll-Keller F., Trimoulet P., Gault E., Chanzy B., Mercier B., Branger M., Pawlotsky J.M., Henquell C., Lunel F., Gaudy-Graffin C., Alain S., Chaix M.L., Duverlie G., Izopet J., Lefrere J.J. Multi-center trials need to use the same assay for hepatitis C virus (HCV) viral load determination. J. Clin. Microbiol., 2007, 45, 3788-90.

Shiffman M.L., Suter F., Bacon B.R., Nelson D., Harley H., Sola R., Shafran S.D., Barange K., Lin A., Soman A., Zeuzem S., Crawford D., Leggett L., Roberts S., Weltman M., Greenbloom S., Menon K., Bourliere M., Brissot P., Bronowicki J.P., Doffoel M., Hezode C., Marcellin P., Tran A., Zarski J.P., Avci O., Berg T., Potthoff O., Rasenack J., Ross O., Von Wagner M., Ascione A., Brillanti S., Brunetto M., Bruno R., Bruno S., Cane E., Aguilar J., Barcena R., Diago M., Enriquez J., Garcia-Samaniego J., Moreno R., Planas R., Rincon D., Sola R., Testillano M., Anand B., Bilir B.B., Balan V., Bank L., Barranco E., Berg C., Bernstein D., Bloom J., Bonkovsky H., Box T., Brau N., Bzowej N., Cassidy W., Clain D., Corasanti J., Davis M., Dejesus E., Delich P., Esposito S., Etzkorn K., Flora K., Fried M., Fromm H., Ghalib R., Gibas A., Godofsky E., Gompf S., Gordon S., Gordon F., Hammond G., Harrison S., Herrera J., Ho S., Howell C., Joshi S., Keeffe E., Kranz K., Kwo P., Lake-Bakaar G., Larson A., Levin A., Lok A., Lucey M., Lyons M., Malet P., Malik P., Manch R., Mehra S., Mihas A., Mikolich D., Morgan T., Muir A., Nguyen R., Nunes D., Nyberg L., O’brien C., Pappas S., Pauly M., Pedrosa M., Perkel M., Person J., Pockros P., Post A., Poulos J., Powell R., Raj V., Reed A., Reindollar R., Riley T., Rodriguez-Torres M., Rubin R., Sahagun G., Schmidt W., Sepe T., Shaw-Stiffel T., Sheikh A., Sherman K., Smith C., Stevens D., Sulkowski M., Toro D., Torres E., Tran T., Tsai N., Wohlman R., Wright W., Wruble L., Younossi Z. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med., 2007, 357, 124-34.

Blanc T., Cortes A., Goere D., Sibert A., Pessaux P., Beghiti J., Sauvanet A. Hemorrhage after pancreaticoduodenectomy: when is surgery still indicated? Am. J. Surg., 2007, 194, 3-9.

Brachet D., Mucci S., Desolneux G., Leboulanger G., Amie F., Pessaux P., Arnaud J.P. The simultaneous occurence of mucinous cystadenomas in liver and pancreas. Eur. J. Gastroenterol. Hepatol., 2007, 19, 801-4.

Lermite E., Pessaux P., Brehant O., Teyssedou C., Pelletier I., Etienne S., Arnaud J.P. Risk factors of pancreatic fistula and delayed gastric emptying after pancreaticoduodenectomy with pancreaticogastrostomy. J. Am. Coll. Surg., 2007, 204, 588-96.

Lermitte E., Regenet N., Tuech J.J., Pessaux P., Meurette G., Bridoux V., Aube C., Arnaud J.P. Diagnosis and treatment of hemosuccus pancreaticus : development of endovascular management. Pancreas, 2007, 34, 229-32.

Mucci-Hennekinne S., Brachet D., Clouston H., Pessaux P., Hamy A., Arnaud J.P. Management of a stenotic pancreatico-digestive tract anastomosis following pancreatoduodenectomy. J. Hepatobiliary Pancreat. Surg., 2007, 14, 514-7.

Holl V., Schmidt S., Aubertin A.M., Moog C. The major population of PHA-stimulated PBMC infected by R5 or X4 HIV variants after a single cycle of infection is predominantly composed of CD45RO(+)CD4 (+) T lymphocytes. Arch of Virol, 2007, 152, 507-518.

 

Baumert T.F., Thimme R., von Weizsacker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol., 2007, 13, 82-90.

Zeisel M.B., Fafi-Kremer S., Fofana I., Barth H., Stoll-Keller F., Doffoël M., Baumert T.F. Neutralizing antibodies in hepatitis C virus infection. World J. Gastroenterol., 2007, 13, 4824-4830.

Fischer R., Baumert T.F., Blum H.E. Hepatitis C virus infection and apoptosis. World J. Gastroenterol., 2007, 13, 4865-4872.

Jaeck D., Pessaux P., Wolf P. Which  types of graft to use in patients with acute liver failure? J. Hepatol., 2007, 46, 570-3.

Fafi-Kremer S., Morand P., Seigneurin J.M. La mononucléose infectieuse revisitée. Virologie, 2007, 11, 13-26.

Gaspard P., Mosnier A., Cohen J.M., Gunther D., Quintle F., Eschbach E., Schwindenhammer R., Stoll-Keller F., Gayet S. Respiratory tract infections in institutions for elderly people : the GROG Géronto-Alsace, strategy of surveillance and alert. Med. Mal. Infect., 2007, 37 (Suppl 3), S215-22.

Lupberger J., Hildt E. Hepatitis B virus-induced oncogenesis. World J. Gastroenterol., 2007, 13, 74-81.

Arntz Y., Ball V., Benkirane-Jessel N., Boulmedais F., Debry C., Dimitrova M., Elkaim R., Haikel Y., Hemmerle J., Lavalle P., Meyer F., Muller S., Ogier J., Schaaf P., Senger B., Stanic V., Tenenbaum H., Vautier D., Vodouhe C., Volodkin D., Voegel J.C., Werner S. Polymers in biomaterials science: from surface functionalisation to tissue engineering. Actualité Chimique, 2007, 310, 20-31.

Fafi-Kremer S., Schvoerer E., Wolf P., Habersetzer F., Doffoel M., Baumert T.F., Stoll-Keller F. Recurrent hepatitis C virus infection after liver transplantation. Current Topics in Virology, 2007, 6, 47-52.

Zeisel M.B., Baumert T.F. Molecular mechanisms of hepatitis C virus entry – Impact of host entry factors of initiation of infection. In: „Genes, Genomes and Genomics, volume three“. (D. Thangadurai, W. Tang, T. Pullaiah eds.), Regency Publications, New Delhi, 2007.

Zarski J.P., Bedossa P., Bronowicki J.P., Doffoel M., Poynard T. Non invasive markers using for the assessment of fibrosis in hepatitis C. Gastroenterol. Clin. Biol., 2007, 31, S34-9.

Fang X., Zeisel M.B., Wilpert J., Barth H., Gissler B., Thimme R., Kreutz C., Maiwald T., Timmer J., Kern W.V., Donauer J., Geyer M., Walz G., Depla E., Von Weizsacker F., Blum H.E., Baumert T.F. Host cell responses induced by hepatitis C virus binding. Hepatology, 2006, 43, 1326-1336.

Barth H., Schnober E.K., Zhang F., Linhardt R.J., Depla E., Boson B., Cosset F.L., Patel A., Blum H.E., Baumert T.F. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J. Virol., 2006, 80, 10579-90.

Neumann-Haefelin C., Mckiernan S., Ward S., Viazov S., Spangenberg H.C., Killinger T., Baumert T.F., Nazarova N., Sheridan I., Pybus O., Von Weizsacker F., Roggendorf M., Kelleher D., Klenerman P., Blum H.E., Thimme R. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology, 2006, 43, 563-572.

Codran A., Royer C., Jaeck D., Bastien-Valle M., Baumert T.F., Kieny M.P., Pereira C.A., Martin J.P. Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J. Gen. Virol., 2006, 87, 2583-2593.

Pivert A., Payan C., Morand P., Fafi-Kemer S., Deshayes J., Carrat F., Pol S., Cacoub P., Perronne C., Lunel F. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin. J. Clin. Microbiol., 2006, 44, 417-422.

Schvoerer E., Thumann C., Spohrer S., Soulier E., Royer C., Brignon N., Doridot S., Meyer N., Ellero B., Woehl-Jaegle M.L., Meyer C., Jaeck D., Wolf P., Stoll-Keller F. Early decrease in circulating dendritic cells number after liver transplantation could favour hepatitis C virus recurrence. J. Med. Virol., 2006, 78, 1070-1075.

Schvoerer E., Frechin V., Fritsch S., Freitag R., Fuchs A., Gut J.P., Stoll-Keller F. Atypical symptoms in patients with herpesvirus DNA detected by PCR in cerebrospinal fluid. J. Clin. Virol., 2006, 35, 458-462.

Choquet S., Leblond V., Herbrecht R., Socie G., Stoppa A.M., Vandenberghe P., Fischer A., Morschhauser F., Salles G., Feremans W., Vilmer E., Peraldi M.N., Lang P., Lebranchu Y., Oksenhendler E., Garnier J.L., Lamy T., Jaccard A., Ferrant A., Offner F., Hermine O., Moreau A., Fafi-Kremer S., Morand P., Chatenoud L., Berriot-Varoqueaux N., Bergougnoux L., Milpied N. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood, 2006, 107, 3053-7.

Zachary P., Wendling M.J., Djeddi S., Schvoerer E., Ullmann M., Stoll-Keller F., Gut J.P. Primary hepatitis C virus infection in an intravenous drug user: kinetics of virological markers. Gastroentérol. Clin. Biol., 2006, 30, 1419-20.

Lupberger J., Mund A., Kock J., Hildt E. Cultivation of HepG2.2.15 on Cytodex-3: higher yield of hepatitis B virus and less subviral particles compared to conventional culture methods. J. Hepatol., 2006, 45, 547-52.

Buerckstuemmer T., Kriegs M., Lupberger J., Pauli E.K., Schmittel S., Hildt E. Raf-1 kinase associates with hepatitis C virus NS5A and regulates viral replication. FEBS Lett., 2006, 580, 575-80.

Toussirot E., Robinet E., Saas P., Chabod J., Auge B., Cozma G., Tiberghien P., Roudier J., Wendling D. Bacterial extract (OM-89) specific and non specific immunomodulation in rheumatoid arthritis patients. Autoimmunity, 2006, 39, 299-306.

Zarski J.P., Marcellin P., Leroy V., Trepo C., Samuel D., Ganne-Carrie N., Barange K., Canva V., Doffoel M., Cales P. Fédération Nationale des Pôles de Référence et des Réseaux Hépatites. Characteristic of patients with chronic hepatitis B in France: predomina frequency of HBe antigen negative cases. J. Hepatol., 2006, 45, 355-60.

Fohrer C., Caillard S., Koumarianou A., Ellero B., Woehl-Jaegle M.L., Meyer C., Epailly E., Chenard M.P., Lioure B., Natarajan-Ame S., Maloisel F., Lutun P., Kessler R., Moulin B., Bergerat J.P., Wolf P., Herbrecht R. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br. J. Haematol., 2006, 134, 602-12.

Kessler L., Lucescu C., Pinget M., Charton M.N., Mutschler V., Wolf P., Berney T., Benhamou P.Y., Gragil Group. Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen. Transplantation, 2006, 81, 636-7.

Barussaud M., Regenet M., Briennon X., De Kerviler B., Pessaux P., Kohneh-Sharhi N., Lehur P.A., Hamy A., Leborgne J., Le Neel J.C., Mirallie E. Clinical spectrum and surgical approach of adult intussusceptions: a multicentric study. Int. J. Colorectal. Dis., 2006, 21, 834-9.

Brehant O., Pessaux P., Arnaud J.P., Delattre J.F., Meyer C., Baulieux J., Mosnier H. Association Française de Chirurgie. Long-term outcome of laparoscopic J. Gastrointest. Surg., 2006, 10, 439-44.

Goere D., Wagholikar G.D., Pessaux P., Carrère N., Sibert A., Vilgrain V., Sauvanet A., Belhiti J. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg. Endosc., 2006, 20, 721-5.

Hennekinne-Mucci S., Tuech J.J., Brehant O., Lermite E., Bergamaschi R., Pessaux P., Arnaud J.P. Emergency subtotal/total colectomy in the management of obstructed left colon carcinoma. Int. J. Colorectal. Dis., 2006, 21, 538-41.

Pessaux P., Arnaud J.P., Delattre J.F., Meyer C., Baulieux J., Mosnier H. Laparoscopic antireflux surgery: five-year results and beyond in 1340 patients. Arch. Surg., 2006, 140, 946-51.

Pessaux P., Kianmanesh R., Regimbeau J.M., Sastre B., Delcenserie R., Sielezneff I., Arnaud J.P., Sauvanet A. Frey procedure in the treatment of chronic pancreatitis: short-term results. Pancreas, 2006, 33, 354-8.

Pessaux P., Lermite E., Blezel E., Msika S., Hay J.M., Flamant Y., Deepak V., Arnaud J.P. French Associations for Surgical Research. Predictive risk score for infection after inguinal hernia repair. Am. J. Surg., 2006, 192, 165-71.

Pessaux P., Lermite E., Brehant O., Tuech J.J., Lorimer G., Arnaud J.P. Repeat hepatectomy for recurrent colorectal liver metastases. J. Surg. Oncol., 2006, 93, 1-7.

Pessaux P., Varma D., Arnaud J.P. Pancreaticoduodenectomy: superior mesenteric artery first approach. J. Gastrointest. Surg., 2006, 10, 607-11.

Reviews/editorials etc.

Barth H., Liang T.J., Baumert T.F. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology, 2006, 44, 527-35.

Zeisel M.B., Baumert T.F. Production of infectious hepatitis C virus in tissue culture: A breakthrough for basic and applied research. J. Hepatol., 2006, 44, 436-9.

Schvoerer E., Thumann C., Soulier E., Royer C., Fafi-Kremer S., Brignon N., Ellero N., Woehl-Jaegle M.L., Meyer C., Wolf P., Jaeck D., Stoll-Keller F. Recurrence of hepatitis C virus (HCV) infection after liver transplantation for HCV-related disease : host factors and viral factors implicated in the occurrence and the severity of HCV recurrence. Pathol. Biol., 2006, 54, 556-560.

Seigneurin J.M., Fafi-Kremer S., Baccard M., Morand P. Diagnostic biologique de l’infection à EBV : actualités en sérologie et en biologie moléculaire. Feuillets de Biologie, 2006, 47, 15-22.

Doffoel M., Ananna A. Palliative treatment of hepatocellular carcinoma. Gastroentérol. Clin. Biol., 2006, 30, 887-90.